Georgina Long
#94,619
Most Influential Person Now
Australian melanoma oncologist and researcher
Georgina Long's AcademicInfluence.com Rankings
Georgina Longmedical Degrees
Medical
#1047
World Rank
#1342
Historical Rank
Oncology
#46
World Rank
#49
Historical Rank
Georgina Longphilosophy Degrees
Philosophy
#4251
World Rank
#6709
Historical Rank
Logic
#1758
World Rank
#2595
Historical Rank
Download Badge
Medical Philosophy
Why Is Georgina Long Influential?
(Suggest an Edit or Addition)According to Wikipedia, Georgina Venetia Long is Co-Medical Director of Melanoma Institute Australia , and Chair of Melanoma Medical Oncology and Translational Research at MIA and Royal North Shore Hospital, The University of Sydney.
Georgina Long's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Nivolumab in previously untreated melanoma without BRAF mutation. (2015) (4628)
- Pembrolizumab versus Ipilimumab in Advanced Melanoma. (2015) (4517)
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. (2015) (3858)
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma (2017) (2731)
- Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. (2012) (2458)
- Genomic Classification of Cutaneous Melanoma (2015) (2143)
- Improved overall survival in melanoma with combined dabrafenib and trametinib. (2015) (2115)
- Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. (2019) (1781)
- Oncogenic Signaling Pathways in The Cancer Genome Atlas (2018) (1646)
- Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. (2014) (1496)
- Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual (2017) (1458)
- Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma (2017) (1456)
- Comprehensive Characterization of Cancer Driver Genes and Mutations (2018) (1360)
- Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis (2018) (1232)
- Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma (2018) (1137)
- Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial (2015) (1097)
- Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy (2017) (980)
- Adjuvant Dabrafenib plus Trametinib in Stage III BRAF‐Mutated Melanoma (2017) (964)
- Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. (2011) (957)
- Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006) (2017) (883)
- Whole-genome landscapes of major melanoma subtypes (2017) (875)
- Targeted agents and immunotherapies: optimizing outcomes in melanoma (2017) (867)
- Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial (2012) (835)
- Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. (2014) (835)
- Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. (2012) (819)
- Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma. (2017) (806)
- Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy. (2017) (727)
- Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. (2019) (692)
- Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab (2016) (618)
- Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. (2018) (615)
- Melanoma whole exome sequencing identifies V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistance (2012) (614)
- Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. (2019) (606)
- Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma (2011) (578)
- Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders. (2016) (513)
- Pathogenic Germline Variants in 10,389 Adult Cancers (2018) (501)
- Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients (2018) (471)
- Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study (2017) (462)
- Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. (2017) (459)
- Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study. (2019) (451)
- Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. (2013) (432)
- BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact (2014) (430)
- Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy. (2019) (393)
- Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma (2012) (392)
- Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. (2013) (381)
- Patterns of somatic structural variation in human cancer genomes (2020) (377)
- Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. (2018) (377)
- Resistance to PD1/PDL1 checkpoint inhibition. (2017) (374)
- Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. (2013) (346)
- PD‐L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti‐PD‐1/PD‐L1 clinical trials (2015) (342)
- Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial. (2017) (312)
- Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. (2022) (301)
- Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors. (2010) (291)
- Immunohistochemistry Is Highly Sensitive and Specific for the Detection of V600E BRAF Mutation in Melanoma (2013) (286)
- Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma (2014) (280)
- Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma (2018) (272)
- Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma (2015) (270)
- Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials. (2016) (270)
- Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib. (2016) (256)
- sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance (2016) (251)
- Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial. (2019) (245)
- CD103+ Tumor-Resident CD8+ T Cells Are Associated with Improved Survival in Immunotherapy-Naïve Melanoma Patients and Expand Significantly During Anti–PD-1 Treatment (2018) (240)
- Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms. (2015) (240)
- Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma (2017) (234)
- Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma (2017) (232)
- Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis. (2014) (231)
- Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017. (2017) (229)
- Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial (2019) (224)
- Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition. (2012) (219)
- Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma (2019) (216)
- Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma (2019) (216)
- Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo (2020) (212)
- High response rate to PD-1 blockade in desmoplastic melanomas (2017) (210)
- Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors (2014) (209)
- Comprehensive molecular characterization of mitochondrial genomes in human cancers (2017) (197)
- Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations (2018) (196)
- Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade (2019) (193)
- Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti–Programmed Cell Death 1 Antibodies (2018) (192)
- Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial. (2017) (190)
- Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context (2018) (188)
- Reactive Neutrophil Responses Dependent on the Receptor Tyrosine Kinase c‐MET Limit Cancer Immunotherapy (2017) (185)
- Circulating Cytokines Predict Immune-Related Toxicity in Melanoma Patients Receiving Anti-PD-1–Based Immunotherapy (2018) (184)
- Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC) (2019) (183)
- Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial. (2015) (183)
- Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor. (2014) (179)
- Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600–Mutant Stage III Melanoma (2018) (176)
- Resistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next? (2016) (174)
- Patterns of Response and Progression to Immunotherapy. (2018) (174)
- Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma (2012) (172)
- Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib. (2017) (172)
- Cutaneous toxicities of RAF inhibitors. (2013) (172)
- Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma (2017) (171)
- Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy (2018) (171)
- Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials (2015) (169)
- A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition. (2014) (157)
- Tumor Genetic Analyses of Patients with Metastatic Melanoma Treated with the BRAF Inhibitor Dabrafenib (GSK2118436) (2013) (157)
- Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets (2019) (155)
- Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma (2021) (153)
- Inhibition of mTORC1/2 overcomes resistance to MAPK pathway inhibitors mediated by PGC1α and oxidative phosphorylation in melanoma. (2014) (152)
- WNT5A enhances resistance of melanoma cells to targeted BRAF inhibitors. (2014) (146)
- Survival of patients with advanced metastatic melanoma: The impact of novel therapies. (2016) (146)
- Targeting BRAF for patients with melanoma (2010) (144)
- Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma. (2020) (143)
- Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials. (2017) (141)
- Evolving concepts in melanoma classification and their relevance to multidisciplinary melanoma patient care (2011) (138)
- Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients (2017) (136)
- Dabrafenib and its potential for the treatment of metastatic melanoma (2012) (132)
- Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436). (2011) (132)
- Dabrafenib and Trametinib, Alone and in Combination for BRAF-Mutant Metastatic Melanoma (2014) (132)
- Systemic treatment for BRAF-mutant melanoma: where do we go next? (2014) (130)
- Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma (2016) (126)
- Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. (2019) (124)
- Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression: Analysis of 2 Phase 3 Clinical Trials (2017) (124)
- Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer (2018) (123)
- Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma (2021) (123)
- Epacadostat (E) plus pembrolizumab (P) versus pembrolizumab alone in patients (pts) with unresectable or metastatic melanoma: Results of the phase 3 ECHO-301/KEYNOTE-252 study. (2018) (123)
- PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor–Treated Melanoma Patients (2015) (121)
- Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. (2021) (119)
- Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition (2020) (119)
- Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial (2020) (116)
- The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma (2015) (113)
- Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma (2018) (112)
- Efficacy analysis of MASTERKEY-265 phase 1b study of talimogene laherparepvec (T-VEC) and pembrolizumab (pembro) for unresectable stage IIIB-IV melanoma. (2016) (112)
- MAPK Signaling and Inflammation Link Melanoma Phenotype Switching to Induction of CD73 during Immunotherapy. (2017) (111)
- Immune checkpoint inhibitors in melanoma (2021) (110)
- BRAF inhibitor activity in V600R metastatic melanoma. (2013) (110)
- FDG-PET response and outcome from anti-PD-1 therapy in metastatic melanoma (2018) (110)
- Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma (2016) (110)
- Tumor-associated B-cells induce tumor heterogeneity and therapy resistance (2017) (105)
- The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma. (2018) (105)
- A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis (2019) (105)
- Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma (2014) (105)
- Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy (2016) (104)
- Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors. (2012) (98)
- Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma (2014) (95)
- Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial. (2019) (94)
- Survival of patients with melanoma brain metastasis treated with stereotactic radiosurgery and active systemic drug therapies. (2017) (91)
- Site‐specific response patterns, pseudoprogression, and acquired resistance in patients with melanoma treated with ipilimumab combined with anti–PD‐1 therapy (2019) (90)
- Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection. (2018) (88)
- A randomized phase 2 study of nivolumab and nivolumab combined with ipilimumab in patients (pts) with melanoma brain metastases: The Anti-PD1 Brain Collaboration (ABC Study). (2016) (88)
- Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: Primary phase III results from RELATIVITY-047 (CA224-047). (2021) (88)
- Genome-wide association meta-analyses combining multiple risk phenotypes provides insights into the genetic architecture of cutaneous melanoma susceptibility (2020) (87)
- 4-year survival and outcomes after cessation of pembrolizumab (pembro) after 2-years in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in KEYNOTE-006. (2018) (86)
- Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial (2022) (85)
- Effect of nivolumab on health-related quality of life in patients with treatment-naïve advanced melanoma: results from the phase III CheckMate 066 study (2016) (83)
- Residual FDG‐PET metabolic activity in metastatic melanoma patients with prolonged response to anti‐PD‐1 therapy (2016) (81)
- Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases (2016) (81)
- The state of melanoma: challenges and opportunities (2016) (79)
- Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trial. (2015) (79)
- Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma. (2019) (79)
- Intratumoral Molecular Heterogeneity in a BRAF-Mutant, BRAF Inhibitor-Resistant Melanoma: A Case Illustrating the Challenges for Personalized Medicine (2012) (78)
- KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma (2020) (78)
- PD-L1 Negative Status is Associated with Lower Mutation Burden, Differential Expression of Immune-Related Genes, and Worse Survival in Stage III Melanoma (2016) (78)
- Inter- and Intra-Patient Heterogeneity of Response and Progression to Targeted Therapy in Metastatic Melanoma (2014) (78)
- Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial. (2018) (77)
- Learning from clinical trials of neoadjuvant checkpoint blockade (2020) (76)
- The nature and management of metastatic melanoma after progression on BRAF inhibitors: Effects of extended BRAF inhibition (2014) (75)
- Epigenetic Changes of EGFR play an important role in BRAF inhibitor Resistant Cutaneous Melanomas (2014) (75)
- Epigenetic profiling for the molecular classification of metastatic brain tumors (2018) (73)
- The Prognostic and Predictive Value of Melanoma-related MicroRNAs Using Tissue and Serum: A MicroRNA Expression Analysis☆ (2015) (72)
- Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma. (2015) (72)
- Intrapatient Homogeneity of BRAFV600E Expression in Melanoma (2014) (72)
- Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma (2020) (70)
- Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival analysis of KEYNOTE-006. (2016) (70)
- Targeting Adenosine in BRAF-Mutant Melanoma Reduces Tumor Growth and Metastasis. (2017) (70)
- Activity of trametinib in K601E and L597Q BRAF mutation-positive metastatic melanoma (2014) (69)
- Genomic analysis and 3-y efficacy and safety update of COMBI-d: A phase 3 study of dabrafenib (D) + trametinib (T) vs D monotherapy in patients (pts) with unresectable or metastatic BRAF V600E/K-mutant cutaneous melanoma. (2016) (69)
- Antiproliferative Effects of Continued Mitogen-Activated Protein Kinase Pathway Inhibition following Acquired Resistance to BRAF and/or MEK Inhibition in Melanoma (2013) (69)
- Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019. (2020) (68)
- SIRT6 haploinsufficiency induces BRAFV600E melanoma cell resistance to MAPK inhibitors via IGF signalling (2018) (68)
- Tumor PD-L1 expression, immune cell correlates and PD-1+ lymphocytes in sentinel lymph node melanoma metastases (2015) (67)
- MicroRNA-130a inhibits cell proliferation, invasion and migration in human breast cancer by targeting the RAB5A. (2015) (66)
- Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma. (2019) (66)
- Whole-genome sequencing of acral melanoma reveals genomic complexity and diversity (2020) (66)
- Whole genome landscapes of uveal melanoma show an ultraviolet radiation signature in iris tumours (2020) (65)
- COMBI-d: A randomized, double-blinded, Phase III study comparing the combination of dabrafenib and trametinib to dabrafenib and trametinib placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAFV600E/K mutation-positive cutaneous melanoma (2014) (64)
- Clinical activity of the MEK inhibitor trametinib in metastatic melanoma containing BRAF kinase fusion (2015) (64)
- Health-related quality of life results from the phase III CheckMate 067 study (2017) (64)
- PD-L1 Expression and Immune Escape in Melanoma Resistance to MAPK Inhibitors (2017) (64)
- Dynamics of Chemokine, Cytokine, and Growth Factor Serum Levels in BRAF-Mutant Melanoma Patients during BRAF Inhibitor Treatment (2014) (64)
- Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial. (2020) (63)
- Acquired resistance to anti-MAPK targeted therapy confers an immune-evasive tumour microenvironment and cross-resistance to immunotherapy in melanoma (2021) (59)
- Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study. (2018) (59)
- Adjuvant Whole-Brain Radiation Therapy Compared With Observation After Local Treatment of Melanoma Brain Metastases: A Multicenter, Randomized Phase III Trial. (2019) (59)
- Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i (2020) (59)
- CD96 Is an Immune Checkpoint That Regulates CD8+ T-cell Antitumor Function (2019) (58)
- Treatment of Melanoma Brain Metastases: A New Paradigm (2012) (58)
- Updated safety and efficacy results from a phase I/II study of the oral BRAF inhibitor dabrafenib (GSK2118436) combined with the oral MEK 1/2 inhibitor trametinib (GSK1120212) in patients with BRAFi-naive metastatic melanoma. (2012) (57)
- LBA43 Spartalizumab plus dabrafenib and trametinib (Sparta-DabTram) in patients (pts) with previously untreated BRAF V600–mutant unresectable or metastatic melanoma: Results from the randomized part 3 of the phase III COMBI-i trial (2020) (57)
- Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study. (2021) (57)
- Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trials. (2014) (57)
- Acneiform eruptions: A common cutaneous toxicity of the MEK inhibitor trametinib (2014) (56)
- Long-term outcomes in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in the phase 3 KEYNOTE-006 study who completed pembrolizumab (pembro) treatment. (2017) (56)
- Targeted Therapy in Advanced Melanoma With Rare BRAF Mutations. (2019) (56)
- Chronic Immune-Related Adverse Events Following Adjuvant Anti-PD-1 Therapy for High-risk Resected Melanoma. (2021) (56)
- Dose selection, pharmacokinetics, and pharmacodynamics of BRAF inhibitor dabrafenib (GSK2118436). (2014) (55)
- Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma. (2019) (55)
- AEBP1 upregulation confers acquired resistance to BRAF (V600E) inhibition in melanoma (2013) (54)
- Systemic therapy in advanced melanoma: integrating targeted therapy and immunotherapy into clinical practice (2017) (54)
- Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond. (2013) (53)
- Checkpoint inhibitor associated autoimmune diabetes (CIADM) is distinct from type 1 diabetes. (2019) (52)
- Integrated molecular and immunophenotypic analysis of NK cells in anti-PD-1 treated metastatic melanoma patients (2018) (52)
- Targeting oncogenic BRAF and aberrant MAPK activation in the treatment of cutaneous melanoma. (2015) (51)
- Preexisting MEK1P124 Mutations Diminish Response to BRAF Inhibitors in Metastatic Melanoma Patients (2014) (50)
- First safety and efficacy results of PRADO: A phase II study of personalized response-driven surgery and adjuvant therapy after neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) in resectable stage III melanoma. (2020) (50)
- Pembrolizumab (pembro) plus ipilimumab (ipi) for advanced melanoma: Results of the KEYNOTE-029 expansion cohort. (2016) (49)
- Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition (2021) (49)
- Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K BRAF-Mutant Melanoma (2019) (49)
- Pembrolizumab (pembro) in combination with dabrafenib (D) and trametinib (T) for BRAF-mutant advanced melanoma: Phase 1 KEYNOTE-022 study. (2016) (49)
- Ipilimumab Combined with Nivolumab: A Standard of Care for the Treatment of Advanced Melanoma? (2016) (48)
- Human Cancer Biology Distinguishing Clinicopathologic Features of Patients with V 600 E and V 600 K BRAF-Mutant Metastatic Melanoma (2012) (47)
- MTOR signaling orchestrates stress-induced mutagenesis, facilitating adaptive evolution in cancer (2020) (46)
- Preliminary results from a phase Ib/II, open-label, dose-escalation study of the oral BRAF inhibitor LGX818 in combination with the oral MEK1/2 inhibitor MEK162 in BRAF V600-dependent advanced solid tumors. (2013) (46)
- KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma. (2019) (46)
- KEYNOTE-022 Part 3: Phase II randomized study of 1L dabrafenib (D) and trametinib (T) plus pembrolizumab (Pembro) or placebo (PBO) for BRAF-mutant advanced melanoma. (2018) (45)
- Prognostic Gene Expression Profiling in Cutaneous Melanoma: Identifying the Knowledge Gaps and Assessing the Clinical Benefit. (2020) (45)
- Molecular Genomic Profiling of Melanocytic Nevi. (2019) (45)
- Targeted BRAF Inhibition Impacts Survival in Melanoma Patients with High Levels of Wnt/β-Catenin Signaling (2014) (45)
- Immune mediated neuropathy following checkpoint immunotherapy (2017) (45)
- Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial (2022) (45)
- Paradoxical oncogenesis: are all BRAF inhibitors equal? (2013) (44)
- Features and management of pyrexia with combined dabrafenib and trametinib in metastatic melanoma (2014) (44)
- (18)F-labelled fluorodeoxyglucose-positron emission tomography (FDG-PET) heterogeneity of response is prognostic in dabrafenib treated BRAF mutant metastatic melanoma. (2013) (43)
- Patterns of response and progression in patients with BRAF‐mutant melanoma metastatic to the brain who were treated with dabrafenib (2014) (43)
- Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study (2019) (42)
- Clinicopathologic features associated with efficacy and long‐term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors (2015) (42)
- Nivolumab improved survival vs dacarbazine in patients with untreated advanced melanoma (2015) (42)
- Erratum: Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy (Cell (2017) 170(6) (1109–1119.e10) (S0092867417309522) (10.1016/j.cell.2017.08.027)) (2018) (42)
- Tumor CD155 Expression Is Associated with Resistance to Anti-PD1 Immunotherapy in Metastatic Melanoma (2020) (41)
- Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy. (2020) (41)
- Systemic retinoids for the chemoprevention of cutaneous squamous cell carcinoma and verrucal keratosis in a cohort of patients on BRAF inhibitors (2013) (41)
- Biomarker Accessible and Chemically Addressable Mechanistic Subtypes of BRAF Melanoma. (2017) (41)
- Sex differences in oncogenic mutational processes (2019) (41)
- Multidisciplinary approach to brain metastasis from melanoma: the emerging role of systemic therapies. (2013) (41)
- Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor GSK2118436 (GSK436). (2011) (41)
- Thyroid immune-related adverse events following immune checkpoint inhibitor treatment. (2021) (40)
- Combined ipilimumab and nivolumab first‐line and after BRAF‐targeted therapy in advanced melanoma (2020) (40)
- Delayed immune-related adverse events with anti-PD1-based immunotherapy in melanoma. (2021) (40)
- Effects of BRAF inhibitors on human melanoma tissue before treatment, early during treatment, and on progression (2013) (40)
- Factors influencing the development of cutaneous squamous cell carcinoma in patients on BRAF inhibitor therapy. (2015) (39)
- Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600–Mutant Unresectable or Metastatic Melanoma (2022) (39)
- [Breast cancer in the early stage]. (2012) (39)
- Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma (2020) (38)
- Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: a clinical validation study. (2021) (38)
- BRAFV600E protein expression and outcome from BRAF inhibitor treatment in BRAFV600E metastatic melanoma (2013) (37)
- CD155 on Tumor Cells Drives Resistance to Immunotherapy by Inducing the Degradation of the Activating Receptor CD226 in CD8+ T Cells. (2020) (37)
- Results of NEMO: A phase III trial of binimetinib (BINI) vs dacarbazine (DTIC) in NRAS-mutant cutaneous melanoma. (2016) (37)
- Close proximity of immune and tumor cells underlies response to anti-PD-1 based therapies in metastatic melanoma patients (2019) (37)
- TMB and Inflammatory Gene Expression Associated with Clinical Outcomes following Immunotherapy in Advanced Melanoma (2021) (37)
- 1216OKEYNOTE-022 update: phase 1 study of first-line pembrolizumab (pembro) plus dabrafenib (D) and trametinib (T) for BRAF-mutant advanced melanoma (2017) (36)
- 1220PDPhase 2 study of neoadjuvant dabrafenib + trametinib (D+T) for resectable stage IIIB/C BRAF V600 mutant melanoma (2017) (36)
- Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma: Pooled Analysis of 3 Clinical Trials. (2020) (35)
- Metastasis‐specific patterns of response and progression with anti‐PD‐1 treatment in metastatic melanoma (2018) (35)
- Pre-operative ctDNA predicts survival in high-risk stage III cutaneous melanoma patients. (2019) (35)
- Longitudinal Monitoring of ctDNA in Patients with Melanoma and Brain Metastases Treated with Immune Checkpoint Inhibitors (2020) (35)
- Combined targeted therapy and immunotherapy in the treatment of advanced melanoma (2012) (34)
- Long-term outcomes from the randomized phase II study of nivolumab (nivo) or nivo+ipilimumab (ipi) in patients (pts) with melanoma brain metastases (mets): Anti-PD1 brain collaboration (ABC) (2019) (33)
- Interleukin-6 blockade for prophylaxis and management of immune-related adverse events in cancer immunotherapy. (2021) (33)
- Cessation of targeted therapy after a complete response in BRAF-mutant advanced melanoma: a case series (2016) (33)
- Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance. (2021) (33)
- Number of primary melanomas is an independent predictor of survival in patients with metastatic melanoma (2012) (33)
- TRIM16 inhibits proliferation and migration through regulation of interferon beta 1 in melanoma cells (2014) (33)
- Whole genome sequencing of melanomas in adolescent and young adults reveals distinct mutation landscapes and the potential role of germline variants in disease susceptibility (2018) (32)
- 1037O MASTERKEY-265: A phase III, randomized, placebo (Pbo)-controlled study of talimogene laherparepvec (T) plus pembrolizumab (P) for unresectable stage IIIB–IVM1c melanoma (MEL) (2021) (32)
- Comparison of whole-exome sequencing of matched fresh and formalin fixed paraffin embedded melanoma tumours: implications for clinical decision making. (2016) (32)
- New combinations and immunotherapies for melanoma: latest evidence and clinical utility (2013) (32)
- The anti–PD-1 antibody spartalizumab (S) in combination with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced BRAF V600–mutant melanoma: Updated efficacy and safety from parts 1 and 2 of COMBI-I. (2019) (32)
- Survival and prognostic factors for patients with melanoma brain metastases in the era of modern systemic therapy (2018) (31)
- Facial palsy as a side effect of vemurafenib treatment in patients with metastatic melanoma. (2013) (31)
- Diagnosis and treatment of KIT-mutant metastatic melanoma. (2013) (31)
- Expression of the class 1 histone deacetylases HDAC8 and 3 are associated with improved survival of patients with metastatic melanoma (2015) (31)
- Ipilimumab‐induced hypophysitis in melanoma patients: an Australian case series (2015) (31)
- Preliminary findings from part 1 of COMBI-i: A phase III study of anti–PD-1 antibody PDR001 combined with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced BRAF V600-mutant melanoma. (2018) (31)
- BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume (2015) (30)
- Phase 1b/2 trial of ribociclib+binimetinib in metastatic NRAS-mutant melanoma: Safety, efficacy, and recommended phase 2 dose (RP2D). (2017) (30)
- Recurrent hotspot SF3B1 mutations at codon 625 in vulvovaginal mucosal melanoma identified in a study of 27 Australian mucosal melanomas (2019) (30)
- Break-MB: a phase II study assessing overall intracranial response rate (OIRR) to dabrafenib (GSK2118436) in patients (pts) with BRAF V600E/k mutation-positive melanoma with brain metastases (mets) (2012) (29)
- BRAF inhibitor (BRAFi) dabrafenib in combination with the MEK1/2 inhibitor (MEKi) trametinib in BRAFi-naive and BRAFi-resistant patients (pts) with BRAF mutation-positive metastatic melanoma (MM). (2013) (29)
- New RAS-mutant pancreatic adenocarcinoma with combined BRAF and MEK inhibition for metastatic melanoma. (2015) (29)
- Circulating Tumor DNA Predicts Outcome from First-, but not Second-line Treatment and Identifies Melanoma Patients Who May Benefit from Combination Immunotherapy (2020) (28)
- Updated overall survival (OS) for BRF113220, a phase 1-2 study of dabrafenib (D) alone versus combined dabrafenib and trametinib (D+T) in pts with BRAF V600 mutation-positive (+) metastatic melanoma (MM). (2014) (27)
- BRAFV600E and NRASQ61L/Q61R mutation analysis in metastatic melanoma using immunohistochemistry: a study of 754 cases highlighting potential pitfalls and guidelines for interpretation and reporting (2016) (27)
- Phase 1b/2, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are naïve to anti-PD-1 therapy. (2018) (27)
- Analysis of molecular mechanisms of response and resistance to vemurafenib (vem) in BRAFV600E melanoma. (2012) (27)
- The molecular profile of metastatic melanoma in Australia. (2016) (27)
- Five-year overall survival from the anti-PD1 brain collaboration (ABC Study): Randomized phase 2 study of nivolumab (nivo) or nivo+ipilimumab (ipi) in patients (pts) with melanoma brain metastases (mets). (2021) (27)
- A Phase I/III, multicenter, open-label trial of talimogene laherparepvec (T-VEC) in combination with pembrolizumab for the treatment of unresected, stage IIIb-IV melanoma (MASTERKEY-265) (2015) (27)
- Replacement and desmoplastic histopathological growth patterns in cutaneous melanoma liver metastases: frequency, characteristics, and robust prognostic value (2020) (26)
- Progression-free survival landmark analysis: a critical endpoint in melanoma clinical trials. (2016) (26)
- Ipilimumab (IPI) alone or in combination with anti-PD-1 (IPI+PD1) in patients (pts) with metastatic melanoma (MM) resistant to PD1 monotherapy. (2020) (26)
- Tumour gene expression signature in primary melanoma predicts long-term outcomes (2020) (26)
- Evaluation of two high-throughput proteomic technologies for plasma biomarker discovery in immunotherapy-treated melanoma patients (2017) (26)
- Hematological immune related adverse events after treatment with immune checkpoint inhibitors. (2021) (26)
- Acute Radiation Skin Toxicity Associated With BRAF Inhibitors. (2016) (25)
- Comprehensive analysis of cutaneous and uveal melanoma liver metastases (2020) (25)
- Anatomic position determines oncogenic specificity in melanoma (2020) (25)
- Abstract CT004: Adjuvant therapy with nivolumab (NIVO) combined with ipilimumab (IPI) vs NIVO alone in patients (pts) with resected stage IIIB-D/IV melanoma (CheckMate 915) (2021) (24)
- Germline BAP1-positive patients: the dilemmas of cancer surveillance and a proposed interdisciplinary consensus monitoring strategy. (2018) (24)
- Incidence of new primary melanomas after diagnosis of stage III and IV melanoma. (2014) (24)
- Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial. (2019) (24)
- Early Use of High-Dose Glucocorticoid for the Management of irAE Is Associated with Poorer Survival in Patients with Advanced Melanoma Treated with Anti–PD-1 Monotherapy (2021) (24)
- Fall in thyroid stimulating hormone (TSH) may be an early marker of ipilimumab-induced hypophysitis (2018) (24)
- First‐in‐human phase 1 study of MK‐1248, an anti–glucocorticoid‐induced tumor necrosis factor receptor agonist monoclonal antibody, as monotherapy or with pembrolizumab in patients with advanced solid tumors (2020) (24)
- The concepts of rechallenge and retreatment with immune checkpoint blockade in melanoma patients. (2021) (24)
- A phase Ib/II dose-escalation study evaluating triple combination therapy with a BRAF (encorafenib), MEK (binimetinib), and CDK 4/6 (ribociclib) inhibitor in patients (Pts) with BRAF V600-mutant solid tumors and melanoma. (2017) (23)
- Prevalence and Cellular Distribution of Novel Immune Checkpoint Targets Across Longitudinal Specimens in Treatment-naïve Melanoma Patients: Implications for Clinical Trials (2019) (23)
- Optimizing combination dabrafenib and trametinib therapy in BRAF mutation‐positive advanced melanoma patients: Guidelines from Australian melanoma medical oncologists (2016) (23)
- Incidence, features and management of radionecrosis in melanoma patients treated with cerebral radiotherapy and anti‐PD‐1 antibodies (2019) (23)
- LBA44 Lenvatinib (len) plus pembrolizumab (pembro) for advanced melanoma (MEL) that progressed on a PD-1 or PD-L1 inhibitor: Initial results of LEAP-004 (2020) (23)
- Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis (2020) (22)
- Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples (2020) (22)
- Novel adjuvant options for cutaneous melanoma. (2021) (22)
- PD-L1 expression as a biomarker for nivolumab (NIVO) plus ipilimumab (IPI) and NIVO alone in advanced melanoma (MEL): A pooled analysis (2016) (22)
- BRAF mutation by age-decade and body mass index in metastatic melanoma. (2011) (22)
- Resistance to PD 1 / PDL 1 checkpoint inhibition (2016) (22)
- Primary anorectal melanoma: clinical, immunohistology and DNA analysis of 43 cases. (2019) (22)
- Dabrafenib plus trametinib is effective in the treatment of BRAF V600-mutated metastatic melanoma patients: analysis of patients from the dabrafenib plus trametinib Named Patient Program (DESCRIBE II) (2019) (21)
- Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: New recurrence-free survival results from the EORTC 1325-MG/Keynote 054 double-blinded phase III trial at three-year median follow-up. (2020) (21)
- Clinical and Pathologic Factors Associated with Distant Metastasis and Survival in Patients with Thin Primary Cutaneous Melanoma (2012) (21)
- Advanced cancer patients’ attitudes towards, and experiences with, screening for somatic mutations in tumours: a qualitative study (2017) (21)
- Disease kinetics for decision-making in advanced melanoma: a call for scenario-driven strategy trials. (2015) (21)
- Tumor MHC Expression Guides First-Line Immunotherapy Selection in Melanoma (2020) (20)
- The role of systemic therapies in the management of melanoma brain metastases (2014) (20)
- Concordant BRAFV600E mutation status in primary melanomas and associated naevi: implications for mutation testing of primary melanomas (2014) (20)
- Updated overall survival (OS) results for BRF113220, a phase I-II study of dabrafenib alone versus combined dabrafenib and trametinib in patients with BRAF V600 metastatic melanoma (MM). (2015) (20)
- The Impact of Nonsteroidal Anti-Inflammatory Drugs, Beta Blockers, and Metformin on the Efficacy of Anti-PD-1 Therapy in Advanced Melanoma. (2019) (20)
- Cumulative Incidence and Predictors of CNS Metastasis for Patients With American Joint Committee on Cancer 8th Edition Stage III Melanoma. (2020) (19)
- Histopathology of pembrolizumab-induced hepatitis: a case report. (2017) (19)
- whole-exome sequencing identifies (2016) (19)
- A multicenter characterization of hepatitis associated with immune checkpoint inhibitors (2021) (19)
- Systemic therapies for melanoma brain metastases: which drug for whom and when? (2015) (19)
- Somatic Hypermutation of the YAP Oncogene in a Human Cutaneous Melanoma (2019) (18)
- Targeted therapies and immune checkpoint inhibitors in the treatment of metastatic melanoma patients: a guide and update for pathologists. (2016) (18)
- Cryopreservation of human cancers conserves tumour heterogeneity for single-cell multi-omics analysis (2020) (18)
- OpACIN-neo: A multicenter phase II study to identify the optimal neo-adjuvant combination scheme of ipilimumab (IPI) and nivolumab (NIVO). (2018) (18)
- Evaluation of stromal HGF immunoreactivity as a biomarker for melanoma response to RAF inhibitors (2013) (18)
- Leptomeningeal melanoma—A case series in the era of modern systemic therapy (2018) (18)
- Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. (2021) (18)
- Phase Ib/II, open-label, dose-escalation study of LGX818, an oral selective BRAF inhibitor, in combination with MEK162, an oral MEK1/2 inhibitor, in patients with BRAF V600-dependent advanced solid tumors: preliminary results (2014) (18)
- Clinical Models to Define Response and Survival With Anti–PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma (2022) (18)
- Twenty-four months RFS and updated toxicity data from OpACIN-neo: A study to identify the optimal dosing schedule of neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) in stage III melanoma. (2020) (17)
- BRAF inhibitor activity in V600R metastatic melanoma--response. (2013) (17)
- Phase 1 study of MK-4166, an anti-human glucocorticoid-induced tumor necrosis factor receptor (GITR) antibody, as monotherapy or with pembrolizumab (pembro) in patients (pts) with advanced solid tumors. (2019) (17)
- Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B (2020) (17)
- Pharmacokinetic and cytokine profiles of melanoma patients with dabrafenib and trametinib-induced pyrexia (2019) (16)
- Impact of baseline serum lactate dehydrogenase concentration on the efficacy of pembrolizumab and ipilimumab in patients with advanced melanoma: data from KEYNOTE-006 (2017) (16)
- The mutational landscape of melanoma brain metastases presenting as the first visceral site of recurrence (2020) (16)
- Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiome (2022) (16)
- Pembrolizumab plus ipilimumab for advanced melanoma : results of the keynote-029 expansion cohort (2016) (16)
- Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis (2022) (16)
- Personalized response-driven adjuvant therapy after combination ipilimumab and nivolumab in high-risk resectable stage III melanoma: PRADO trial. (2019) (16)
- 1213OCharacterization of complete responses (CRs) in patients with advanced melanoma (MEL) who received the combination of nivolumab (NIVO) and ipilimumab (IPI), NIVO or IPI alone (2017) (16)
- Bempegaldesleukin plus nivolumab in untreated, unresectable or metastatic melanoma: Phase III PIVOT IO 001 study design. (2020) (16)
- 24LBA Safety data from the phase 1b part of the MASTERKEY-265 study combining talimogene laherparepvec (T-VEC) and pembrolizumab for unresectable stage IIIB-IV melanoma (2015) (16)
- Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders (AD) or major toxicity with ipilimumab (IPI). (2016) (16)
- A multicenter, open-label trial of talimogene laherparepvec (T-VEC) plus pembrolizumab vs pembrolizumab monotherapy in previously untreated, unresected, stage IIIB-IV melanoma. (2015) (16)
- Long-term benefit of adjuvant dabrafenib + trametinib (D+T) in patients (pts) with resected stage III BRAF V600–mutant melanoma: Five-year analysis of COMBI-AD. (2020) (16)
- Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma (2022) (15)
- Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy (2021) (15)
- Design and Testing of a Custom Melanoma Next Generation Sequencing Panel for Analysis of Circulating Tumor DNA (2020) (15)
- Multicenter phase 2 study to identify the optimal neo-adjuvant combination scheme of ipilimumab (IPI) and nivolumab (NIVO) (OpACIN-neo). (2017) (15)
- Inter‐ and intrapatient heterogeneity of indoleamine 2,3‐dioxygenase expression in primary and metastatic melanoma cells and the tumour microenvironment (2019) (15)
- KEYNOTE-006 study of pembrolizumab (pembro) versus ipilimumab (ipi) for advanced melanoma: Efficacy by PD-L1 expression and line of therapy. (2016) (15)
- 429 Long-term analysis of MASTERKEY-265 phase 1b trial of talimogene laherparepvec (T-VEC) plus pembrolizumab in patients with unresectable stage IIIB-IVM1c melanoma (2020) (15)
- Targeting melanoma with front-line therapy does not abrogate Nodal-expressing tumor cells (2017) (15)
- Computer-assisted diagnosis for skin cancer: have we been outsmarted? (2017) (15)
- Targeting NK Cells to Enhance Melanoma Response to Immunotherapies (2021) (14)
- Updated relapse-free survival (RFS) and biomarker analysis in the COMBI-AD trial of adjuvant dabrafenib + trametinib (D + T) in patients (pts) with resected BRAF V600-mutant stage III melanoma. (2018) (14)
- Clinicopathological characteristics and management of colitis with anti-PD1 immunotherapy alone or in combination with ipilimumab (2020) (14)
- Pretreatment Innate Cell Populations and CD4 T Cells in Blood Are Associated With Response to Immune Checkpoint Blockade in Melanoma Patients (2020) (14)
- Histological diagnosis of immune checkpoint inhibitor induced acute renal injury in patients with metastatic melanoma: a retrospective case series report (2020) (14)
- 18-months relapse-free survival (RFS) and biomarker analyses of OpACIN-neo: A study to identify the optimal dosing schedule of neoadjuvant (neoadj) ipilimumab (IPI) + nivolumab (NIVO) in stage III melanoma (2019) (14)
- Long-term survival from pembrolizumab (pembro) completion and pembro retreatment: Phase III KEYNOTE-006 in advanced melanoma. (2020) (14)
- Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial. (2022) (14)
- Lesion-specific patterns of response and progression with anti-PD-1 treatment in metastatic melanoma (MM). (2014) (14)
- Pathological response and tumour bed histopathological features correlate with survival following neoadjuvant immunotherapy in stage III melanoma. (2021) (14)
- Histopathological features of complete pathological response predict recurrence-free survival following neoadjuvant targeted therapy for metastatic melanoma. (2020) (14)
- Effect of Aidi injection plus chemotherapy on gastric carcinoma: a Meta-analysis of randomized controlled trials. (2015) (14)
- Melanoma and immunotherapy bridge 2015 (2016) (13)
- Clinical significance of intronic variants in BRAF inhibitor resistant melanomas with altered BRAF transcript splicing (2017) (13)
- Analysis of the Whole-Exome Sequencing of Tumor and Circulating Tumor DNA in Metastatic Melanoma (2019) (13)
- Multiple Gastrointestinal Polyps in Patients Treated with BRAF Inhibitors (2015) (13)
- Health-related quality-of-life results for pembrolizumab versus placebo after complete resection of high-risk stage III melanoma from the EORTC 1325-MG/Keynote 054 trial: An international randomized double-blind phase III trial. (2018) (13)
- Efficacy of immune checkpoint inhibitors for in-transit melanoma (2020) (13)
- Lenvatinib (len) plus pembrolizumab (pembro) for patients (pts) with advanced melanoma and confirmed progression on a PD-1 or PD-L1 inhibitor: Updated findings of LEAP-004. (2021) (13)
- Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC) (2022) (13)
- Relatlimab and nivolumab versus nivolumab in previously untreated metastatic or unresectable melanoma: Overall survival and response rates from RELATIVITY-047 (CA224-047) (2022) (13)
- Representativeness of the Index Lymph Node for Total Nodal Basin in Pathologic Response Assessment After Neoadjuvant Checkpoint Inhibitor Therapy in Patients With Stage III Melanoma. (2022) (13)
- Adverse events 2.0-Let us get SERIOs: New reporting for adverse event outcomes needed in the era of immunooncology. (2019) (13)
- The Impact of Nonsteroidal Anti-Inflammatory Drugs, Beta Blockers, and Metformin on the Efficacy of Anti-PD-1 Therapy in Advanced Melanoma. (2020) (13)
- Phase I Study of MK-4166, an Anti-human Glucocorticoid-Induced TNF Receptor Antibody, Alone or with Pembrolizumab in Advanced Solid Tumors (2020) (13)
- Management of melanoma brain metastases: Evidence-based clinical practice guidelines by Cancer Council Australia. (2020) (13)
- Phase 2 study of the safety and efficacy of pembrolizumab (pembro) in combination with dabrafenib (D) and trametinib (T) for advanced melanoma (KEYNOTE-022). (2016) (13)
- Temporal and spatial modulation of the tumor and systemic immune response in the murine Gl261 glioma model (2020) (13)
- A phase II, open label, randomized controlled trial of nivolumab plus ipilimumab with stereotactic radiotherapy versus ipilimumab plus nivolumab alone in patients with melanoma brain metastases (ABC-X Trial). (2019) (12)
- Phase 2 study of neoadjuvant dabrafenib + trametinib (D+T) for resectable stage iiib/c BRAF-V600 mutation positive melanoma. (2016) (12)
- First-in-human phase 1 study of MK-1248, an anti-human glucocorticoid-induced tumor necrosis factor receptor (GITR) monoclonal antibody, as monotherapy or in combination with pembrolizumab in patients with advanced solid tumors. (2018) (12)
- Preliminary results from the international neoadjuvant melanoma consortium (INMC). (2017) (12)
- Safety and efficacy of anti-PD-1 antibodies in elderly patients with metastatic melanoma (2016) (12)
- G9a Inhibition Enhances Checkpoint Inhibitor Blockade Response in Melanoma (2021) (12)
- Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. (2019) (12)
- Phase 1 study of the p53-MDM2 inhibitor AMG 232 combined with trametinib plus dabrafenib or trametinib in patients (Pts) with TP53 wild type (TP53WT) metastatic cutaneous melanoma (MCM). (2017) (12)
- Clinical characteristics and survival of BRAF-mutant (BRAF+) metastatic melanoma patients (pts) treated with BRAF inhibitor (BRAFi) dabrafenib or vemurafenib beyond disease progression (PD). (2013) (12)
- Abstract CT182: The anti-PD-1 antibody spartalizumab (PDR001) in combination with dabrafenib and trametinib in previously untreated patients with advancedBRAFV600-mutant melanoma: First efficacy, safety, and biomarker findings from the part 2 biomarker cohort of COMBi-i (2018) (12)
- Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy (2022) (11)
- NEMO: A phase 3 trial of binimetinib (MEK162) versus dacarbazine in patients with untreated or progressed after first-line immunotherapy unresectable or metastatic NRAS-mutant cutaneous melanoma. (2014) (11)
- LBA3 Pembrolizumab versus placebo after complete resection of high-risk stage II melanoma: Efficacy and safety results from the KEYNOTE-716 double-blind phase III trial (2021) (11)
- Multiple checkpoints on the long road towards cancer immunotherapy (2015) (11)
- Intra-patient heterogeneity of BRAF mutation status: fact or fiction? (2013) (11)
- FDG-PET to predict long-term outcome from anti-PD1 therapy in metastatic melanoma. (2021) (11)
- 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two (2016) (11)
- Recurrent bowel obstruction: unusual presentation of pembrolizumab-induced pancreatitis in annular pancreas. (2017) (11)
- Response to anti-PD1/PDL1 therapy in patients with metastatic desmoplastic melanoma. (2015) (11)
- Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules (2021) (11)
- Immunotherapy in patients with concurrent solid organ transplant, HIV, and Hepatitis B and C (2017) (11)
- Prognostic and predictive value of an immune-related adverse event among stage III melanoma patients included in the EORTC 1325/KEYNOTE-054 pembrolizumab versus placebo trial. (2019) (11)
- Mucosal‐associated invariant T (MAIT) cells are activated in the gastrointestinal tissue of patients with combination ipilimumab and nivolumab therapy‐related colitis in a pathology distinct from ulcerative colitis (2020) (11)
- 3305 PD1 inhibition-induced changes in melanoma and its associated immune infiltrate (2015) (10)
- Tumor Mutation Burden and Structural Chromosomal Aberrations Are Not Associated with T-cell Density or Patient Survival in Acral, Mucosal, and Cutaneous Melanomas (2020) (10)
- Re-challenge with BRAF-directed treatment: A multi-institutional retrospective study. (2017) (10)
- Optimal systemic therapy for high-risk resectable melanoma (2022) (10)
- Effect of nivolumab (NIVO) on quality of life (QoL) in patients (pts) with treatment-naïve advanced melanoma (MEL): Results of a phase III study (CheckMate 066). (2015) (10)
- KEYNOTE-029: Efficacy and safety of pembrolizumab (pembro) plus ipilimumab (ipi) for advanced melanoma. (2017) (10)
- Effect on health-related quality of life (HRQOL) of adjuvant treatment (tx) with dabrafenib plus trametinib (D + T) in patients (pts) with resected stage III BRAF-mutant melanoma. (2018) (10)
- A multicenter analysis of melanoma recurrence following adjuvant anti-PD1 therapy. (2019) (10)
- Association of anti-thyroid antibodies in checkpoint inhibitor associated thyroid immune related adverse events. (2022) (10)
- Activity of targeted therapy after failure of first-line immunotherapy in BRAF-mutant metastatic melanoma. (2018) (10)
- Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915) (2022) (10)
- Abstract 4217: Tumor mutational burden (TMB), T cell-inflamed gene expression profile (GEP) and PD-L1 are independently associated with response to pembrolizumab (Pembro) in patients with advanced melanoma in the KEYNOTE (KN)-006 study (2019) (10)
- Utility of 1-year FDG-PET (PET) to determine outcomes from anti-PD-1 (PD1) based therapy in patients (pts) with metastatic melanoma (MM). (2018) (10)
- The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis. (2021) (9)
- Dabrafenib plus trametinib (D + T) as adjuvant treatment of resected BRAF-mutant stage III melanoma: Findings from the COMBI-AD trial analyzed based on AJCC 8 classification. (2018) (9)
- 1082MO 5-year characterization of complete responses in patients with advanced melanoma who received nivolumab plus ipilimumab (NIVO+IPI) or NIVO alone (2020) (9)
- Expanded access programmes: patient interests versus clinical trial integrity. (2015) (9)
- Oral malignant gastrointestinal neuroectodermal tumour with junctional component mimicking mucosal melanoma. (2018) (9)
- 1130TiPNEMO: A PHASE 3 TRIAL OF BINIMETINIB (MEK162) VERSUS DACARBAZINE IN PATIENTS WITH ADVANCED NRAS-MUTANT MELANOMA WHO ARE UNTREATED OR HAVE PROGRESSED AFTER ANY NUMBER OF IMMUNOTHERAPY REGIMENS. (2014) (9)
- A phase II study of the multitargeted kinase inhibitor lenvatinib in patients with advanced BRAF wild-type melanoma. (2013) (9)
- MicroRNA-130 a inhibits cell proliferation , invasion and migration in human breast cancer by targeting the RAB 5 A (2015) (9)
- Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma. (2021) (9)
- Circulating Tumor DNA Reflects Uveal Melanoma Responses to Protein Kinase C Inhibition (2021) (9)
- Genetic drivers of non‐cutaneous melanomas: Challenges and opportunities in a heterogeneous landscape (2021) (9)
- Abstract S02-01: Clinical characteristics and outcomes of coronavirus 2019 disease (COVID-19) in cancer patients treated with immune checkpoint inhibitors (ICI) (2020) (9)
- Five-year overall survival (OS) update from a phase II, open-label trial of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600–mutant unresectable or metastatic melanoma (MM). (2017) (8)
- COMBI-MB: A phase II study of combination dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600–mutant (mut) melanoma brain metastases (MBM). (2017) (8)
- Comparison of BRAF inhibitor (BRAFi)-induced cutaneous squamous cell carcinoma (cuSCC) and secondary malignancies in BRAF mutation-positive metastatic melanoma (MM) patients (pts) treated with dabrafenib (D) as monotherapy or in combination with MEK1/2 inhibitor (MEKi) trametinib (T). (2013) (8)
- Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders (2021) (8)
- Personalized combination of neoadjuvant domatinostat, nivolumab and ipilimumab in macroscopic stage III melanoma patients stratified according to the interferon-gamma signature: The DONIMI study. (2020) (8)
- Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006 (2021) (8)
- Atrophic exocrine pancreatic insufficiency associated with anti-PD1 therapy. (2016) (8)
- Radiological manifestations of immune‐related adverse effects observed in patients with melanoma undergoing immunotherapy (2017) (8)
- Neoadjuvant ipilimumab plus nivolumab in synchronous clinical stage III melanoma. (2021) (8)
- Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy (2022) (8)
- Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination (2022) (8)
- Pyrexia in patients treated with dabrafenib plus trametinib across clinical trials in BRAF-mutant cancers. (2021) (8)
- The anti–PD-1 antibody spartalizumab in combination with dabrafenib and trametinib in advanced BRAF V600–mutant melanoma: Efficacy and safety findings from parts 1 and 2 of the Phase III COMBI-i trial. (2020) (8)
- Clinical and Molecular Heterogeneity in Patients with Innate Resistance to Anti-PD-1 +/− Anti-CTLA-4 Immunotherapy in Metastatic Melanoma Reveals Distinct Therapeutic Targets (2021) (8)
- LBA39 Personalized combination of neoadjuvant domatinostat, nivolumab (NIVO) and ipilimumab (IPI) in stage IIIB-D melanoma patients (pts) stratified according to the interferon-gamma signature (IFN-γ sign): The DONIMI study (2021) (8)
- Patterns of progression in patients (pts) with V600 BRAF-mutated melanoma metastatic to the brain treated with dabrafenib (GSK2118436). (2012) (8)
- Addition of interleukin-2 overcomes resistance to neoadjuvant CTLA4 and PD1 blockade in ex vivo patient tumors (2022) (8)
- RAF Inhibitor Dabrafenib (GSK2118436) is Active in Melanoma Brain Metastases, Multiple BRAF Genotypes and Diverse Cancers (2014) (8)
- PDCD1 Polymorphisms May Predict Response to Anti-PD-1 Blockade in Patients With Metastatic Melanoma (2021) (7)
- 1256TiPA Phase II, Randomised, Open Label Study of Neoadjuvant Pembrolizumab with/without Dabrafenib and Trametinib (D+T) in BRAF V600 Mutant Resectable Stage IIIB/C/D Melanoma (NeoTrio Trial) (2017) (7)
- Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition. (2021) (7)
- Clinico-pathologic correlates of BRAF mutation status in 207 consecutive patients with metastatic melanoma. (2010) (7)
- Overall survival in COMBI-d, a randomized, double-blinded, phase III study comparing the combination of dabrafenib and trametinib with dabrafenib and placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAF V600E/Kmutation-positive cutaneous melanoma. (2015) (7)
- Hyperacute toxicity with combination ipilimumab and anti-PD1 immunotherapy. (2021) (7)
- Benefit and toxicity of programmed death‐1 blockade vary by ethnicity in patients with advanced melanoma: an international multicentre observational study * (2022) (7)
- The efficacy of immunotherapy for in-transit metastases of melanoma: an analysis of randomized controlled trials (2021) (7)
- Anti-CTLA-4 probody BMS-986249 alone or in combination with nivolumab in patients with advanced cancers: Initial phase I results. (2020) (7)
- A phase 1/3 multicenter trial of talimogene laherparepvec in combination with pembrolizumab for unresected, stage IIIB-IV melanoma (MASTERKEY-265). (2016) (7)
- BRAF +/- MEK inhibition following pembrolizumab (pembro) in KEYNOTE-006 (2018) (7)
- Metastatic acral melanoma treatment outcomes: a systematic review and meta-analysis (2019) (6)
- Abstract CT188: 5-year survival and other long-term outcomes from KEYNOTE-006 study of pembrolizumab (pembro) for ipilimumab (ipi)-naive advanced melanoma (2019) (6)
- Five-year analysis on the long-term effects of dabrafenib plus trametinib (D + T) in patients with BRAF V600–mutant unresectable or metastatic melanoma. (2019) (6)
- Abstract 2822: Low intestinal microbial diversity is associated with severe immune-related adverse events and lack of response to neoadjuvant combination antiPD1, anti-CTLA4 immunotherapy (2019) (6)
- The “Tricky Business” of Identifying Mechanisms of Resistance to Anti–PD-1 (2017) (6)
- Distinct patterns of response and toxicity (tox) by sites of metastases (mets) in patients (pts) treated with ipilimumab combined with PD-1 antibodies (ipi+PD1). (2018) (6)
- Cryopreservation of human cancers conserves tumour heterogeneity for single-cell multi-omics analysis (2021) (6)
- Integration of Digital Pathologic and Transcriptomic Analyses Connects Tumor-Infiltrating Lymphocyte Spatial Density With Clinical Response to BRAF Inhibitors (2020) (6)
- Recent Developments in Melanoma Therapy. (2016) (6)
- Abstract 3412: 36-months and 18-months relapse-free survival after (neo)adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma patients - update of the OpACIN and OpACIN-neo trials (2020) (6)
- Hypermethylation of Circulating Free DNA in Cutaneous Melanoma (2019) (6)
- Survival Outcomes of Salvage Metastasectomy After Failure of Modern-Era Systemic Therapy for Melanoma (2021) (6)
- Corrigendum: sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance (2016) (6)
- Morphologic and immunohistochemical (IHC) changes in metastatic melanoma (MM) tissue and associations with clinical outcome in patients (pts) on BRAF inhibitors (BRAFi). (2011) (6)
- Publisher Correction: Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma (2019) (6)
- BRAF inhibitor acquired resistance: A multicenter meta-analysis of the spectrum and clinical implications of resistance mechanisms. (2015) (6)
- Abstract 5734: Gut microbiota predicts response and toxicity with neoadjuvant immunotherapy (2020) (6)
- Melanoma with osseous or chondroid differentiation: a report of eight cases including SATB2 expression and mutation analysis. (2021) (6)
- Proteomic phenotyping of metastatic melanoma reveals putative signatures of MEK inhibitor response and prognosis (2018) (6)
- Multiplex melanoma families are enriched for polygenic risk (2020) (6)
- Molecular and immunological associations of elevated serum lactate dehydrogenase in metastatic melanoma patients: A fresh look at an old biomarker (2020) (6)
- Pooled analysis of safety over time and link between adverse events and efficacy across combination dabrafenib and trametinib (D+T) registration trials. (2016) (6)
- Detection of BRAF splicing variants in plasma-derived cell-free nucleic acids and extracellular vesicles of melanoma patients failing targeted therapy therapies (2020) (6)
- Neoadjuvant BRAF (dabrafenib) and MEK (trametinib) inhibition for high-risk resectable stage III and IV melanoma (2015) (6)
- Atrophic exocrine pancreatic insufficiency associated with anti-PD1 therapy. (2017) (5)
- From dismal prognosis to rising star: melanoma leads the way with new generation cancer therapies (2015) (5)
- Incidence, features and management of radionecrosis (RN) in melanoma patients (pts) treated with cerebral radiotherapy (RT) and anti-PD-1 antibodies (PD1). (2017) (5)
- Prognostic and predictive value of β-blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma. (2022) (5)
- Phase Ib/II study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who had progressive disease on or after prior anti-PD-1 therapy. (2018) (5)
- Five-Year Analysis of Adjuvant Pembrolizumab or Placebo in Stage III Melanoma (2022) (5)
- Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma (2022) (5)
- Characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis: A retrospective multicentre cohort study. (2022) (5)
- Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase 3 trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma. (2021) (5)
- Higher proportions of CD39+ tumor-resident cytotoxic T cells predict recurrence-free survival in patients with stage III melanoma treated with adjuvant immunotherapy (2022) (5)
- 3302 Safety and Activity of Combined Radiotherapy (RT) and Anti-PD-1 Antibodies (PD-1) in Patients (pts) with Metastatic Melanoma (2015) (5)
- CTLA-4 Blockade Resistance after Relatlimab and Nivolumab. (2022) (5)
- Heterogeneity of FDG-PET response to GSK2118436, an inhibitor of oncogenic mutant BRAF-kinase in BRAF-mutant metastatic melanoma. (2011) (5)
- Survival update of neoadjuvant ipilimumab + nivolumab in macroscopic stage III melanoma: The OpACIN and OpACIN-neo trials. (2022) (5)
- Unraveling the prognostic heterogeneity in patients with advanced melanoma between Australia (OZ) and the United States (US): Preliminary report of the PHAMOUS study. (2010) (5)
- Identifying challenges to implementation of clinical practice guidelines for sentinel lymph node biopsy in patients with melanoma in Australia: protocol paper for a mixed methods study (2020) (5)
- Determining optimal sequencing of anti-PD-1 and BRAF-targeted therapy: A phase II randomised study of neoadjuvant pembrolizumab with/without dabrafenib and trametinib (D+T) in BRAF V600 mutant resectable stage IIIb/c/d melanoma (NeoTrio trial). (2018) (5)
- External validation of a prognostic model to predict survival of patients with sentinel node‐negative melanoma (2019) (5)
- Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment (2022) (4)
- Avelumab (MSB0010718C; anti-PD-L1) in combination with other cancer immunotherapies in patients with advanced malignancies: The phase 1b/2 JAVELIN Medley study. (2016) (4)
- Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria. (2022) (4)
- Pyrexia-related outcomes upon application of an adapted pyrexia management algorithm in patients (pts) with BRAF V600: Mutant unresectable or metastatic melanoma treated with dabrafenib plus trametinib (DabTram) in the COMBI-i trial. (2021) (4)
- Unveiling the tumor immune microenvironment of organ-specific melanoma metastatic sites (2022) (4)
- Optimum dosing of ipilimumab in melanoma: too little, too late? (2017) (4)
- Characteristics of pyrexia in BRAF V 600 E / K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I / II clinical trial (2015) (4)
- Grade 4 Neutropenia Secondary to Immune Checkpoint Inhibition — A Descriptive Observational Retrospective Multicenter Analysis (2021) (4)
- Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition (2020) (4)
- Double Trouble: Immunotherapy Doublets in Melanoma-Approved and Novel Combinations to Optimize Treatment in Advanced Melanoma. (2022) (4)
- L3 Update of the OpACIN and OpACIN-neo trials: 36-months and 24-months relapse-free survival after (neo)adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma patients (2020) (4)
- Distinct pretreatment innate immune landscape and posttreatment T cell responses underlie immunotherapy-induced colitis (2022) (4)
- The Effect of Immune Checkpoint Inhibitors in Patients with Concomitant Advanced Melanoma and Chronic Lymphocytic Leukaemia (2017) (4)
- Targeting the Microbiome to Overcome Resistance. (2021) (4)
- The use of vemurafenib in Australian patients with unresectable or metastatic melanoma containing the V600 BRAF gene mutation (2014) (4)
- Neurotoxicity associated with anti-PD1 therapy: A multi-center case series. (2017) (4)
- LBA6_PRCOMBI-AD: Adjuvant dabrafenib (D) plus trametinib (T) for resected stage III BRAF V600E/K–mutant melanoma (2017) (4)
- KEYNOTE - D36: personalized immunotherapy with a neoepitope vaccine, EVX-01 and pembrolizumab in advanced melanoma. (2022) (4)
- Diagnostic utility of PRAME, p53 and 5-hmC immunostaining for distinguishing melanomas from naevi, neurofibromas, scars and other histological mimics. (2022) (4)
- Risk of radiation necrosis after stereotactic radiosurgery for melanoma brain metastasis by anatomical location (2021) (4)
- Role of Tumor-Infiltrating B Cells in Clinical Outcome of Patients with Melanoma Treated With Dabrafenib Plus Trametinib (2021) (4)
- Tumor-specific circulating cell-free DNA (cfDNA) BRAF mutations (muts) to predict clinical outcome in patients (pts) treated with the BRAF inhibitor dabrafenib (GSK2118436). (2012) (4)
- Correlates of fever in patients (pts) receiving combined dabrafenib (GSK2118436) plus trametinib (GSK1120212) for V600 BRAF-mutant metastatic melanoma (MM). (2012) (4)
- Interim analysis of a phase Ib study of cobimetinib plus atezolizumab in patients with advanced BRAFV600 wild type melanoma progressing on prior anti-PD-L1 therapy (2019) (4)
- Re-induction ipilimumab following acquired resistance to combination ipilimumab and anti-PD-1 therapy. (2021) (4)
- High-Dimensional Single-Cell Transcriptomics in Melanoma and Cancer Immunotherapy (2021) (4)
- Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma (2022) (4)
- The efficacy of immune checkpoint blockade for melanoma in-transit with or without nodal metastases e A multicenter cohort study (2022) (4)
- Primary medical therapy for BRAFV600E-mutant melanoma brain metastases-is this good enough? - Authors' reply. (2017) (3)
- PIVOT-12: a Phase III study of adjuvant bempegaldesleukin plus nivolumab in resected stage III/IV melanoma at high risk for recurrence. (2022) (3)
- Comprehensive molecular profiling of metastatic melanoma to predict response to monotherapy and combination immunotherapy. (2019) (3)
- Omitting radiosurgery in melanoma brain metastases: a drastic and dangerous de-escalation - Authors' reply. (2018) (3)
- Feasibility, acceptability, and utility of a nurse-led survivorship program for people with metastatic melanoma (MELCARE) (2022) (3)
- Intestinal microbiota predict response and toxicities during anti-PD-1/anti-CTLA-4 immunotherapy (2020) (3)
- 3337 Safety and effectiveness analysis of V600 BRAF-mutated metastatic melanoma (MM) patients (pts) from the dabrafenib (D) plus trametinib (T) named patient programme (NPP) - DESCRIBE II study (2015) (3)
- Combination of the STING Agonist MIW815 and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-label, Multicenter, Phase Ib Study. (2022) (3)
- Reply to M. Perier-Muzet et al. (2014) (3)
- IL-6 blockade for prophylaxis and management of immune-related adverse events (irAEs) with anti-PD-1 based immunotherapy. (2021) (3)
- Adverse event (AE) kinetics in patients (pts) treated with dabrafenib + trametinib (D + T) in the metastatic and adjuvant setting (2019) (3)
- Hyperacute toxicity with combination ipilimumab (ipi) and anti-PD1 immunotherapy. (2018) (3)
- Impact of genomics on the surgical management of melanoma (2018) (3)
- LESION-SPECIFIC PATTERNS OF RESPONSE AND PROGRESSION WITH ANTI-PD-1 TREATMENT IN METASTATIC MELANOMA (MM) (2014) (3)
- Standard-dose pembrolizumab (pembro) plus alternate-dose ipilimumab (ipi) in advanced melanoma: Initial analysis of KEYNOTE-029 cohort 1C. (2019) (3)
- Combination anti-PD-1 and ipilimumab (ipi) therapy in patients with advanced melanoma and pre-existing autoimmune disorders (AD). (2020) (3)
- The impact of multiple primary cutaneous melanomas on survival of 2,942 patients with metastatic melanoma. (2010) (3)
- Efficacy Outcomes in the Phase 3 COMBI-AD Study of Adjuvant Dabrafenib Plus Trametinib vs Placebo in Patients with Stage III BRAFV600E/K-Mutant Melanoma (2018) (3)
- Synergistic effects of MAPK and immune checkpoint inhibitors in melanoma: what is the best combination strategy? (2015) (3)
- Abstract 975: Liver metastases (mets) induce systemic immunosuppression and immunotherapy resistance in metastatic melanoma (2019) (3)
- Pembrolizumab versus placebo as adjuvant therapy in resected high-risk stage II melanoma: Phase 3 KEYNOTE-716 study. (2019) (3)
- CA045-001: A phase III, randomized, open label study of bempegaldesleukin (NKTR-214) plus nivolumab (NIVO) versus NIVO monotherapy in patients (pts) with previously untreated, unresectable or metastatic melanoma (MEL). (2019) (3)
- Abstract CT101: Phase III study of pembrolizumab (MK-3475) versus ipilimumab in patients with ipilimumab-naive advanced melanoma (2015) (3)
- Adverse events (AEs) over time in patients (pts) treated with adjuvant dabrafenib plus trametinib (D + T) or placebo (Pbo) in the COMBI-AD trial. (2018) (3)
- Multi-trait genetic analysis identifies auto-immune loci associated with cutaneous melanoma. (2021) (3)
- Distinct gene expression, mutational profile and clinical outcomes of V600E and V600K/R BRAF-mutant metastatic melanoma (MM). (2017) (3)
- Genome-wide association meta-analyses combining multiple risk phenotypes provide insights into the genetic architecture of cutaneous melanoma susceptibility (2020) (3)
- Phase 1b/2, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced/metastatic melanoma resistant to anti-PD-1/PD-L1 therapy. (2019) (3)
- Phase Ib/II, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are naïve to anti-PD-1 therapy. (2018) (3)
- Detailed spatial immunophenotyping of primary melanomas reveals immune cell subpopulations associated with patient outcome (2022) (3)
- 1085P Health-related quality of life in stage III melanoma patients treated with neoadjuvant ipilimumab and nivolumab followed by index lymph node excision only versus therapeutic lymph node dissection: 24-week results of the PRADO trial (2020) (3)
- IFN-γ signature enables selection of neoadjuvant treatment in patients with stage III melanoma (2023) (3)
- Pembrolizumab (pembro) plus dabrafenib (dab) and trametinib (tram) in BRAFV600E/K-mutant melanoma: Long-term follow-up of KEYNOTE-022 parts 1, 2, and 3. (2022) (3)
- Validation of an Accurate Automated Multiplex Immunofluorescence Method for Immuno-Profiling Melanoma (2022) (3)
- 509 A first-in-human phase 1 study of NL-201 in patients with relapsed or refractory cancer (2021) (2)
- Effect of first-line spartalizumab + dabrafenib + trametinib on immunosuppressive features detected in peripheral blood and clinical outcome in patients (pts) with advanced BRAF V600–mutant melanoma. (2020) (2)
- bcGST—an interactive bias‐correction method to identify over‐represented gene‐sets in boutique arrays (2018) (2)
- Analysis of circulating tumor DNA (ctDNA) in pseudoprogression in anti-PD1 treated metastatic melanoma (MM). (2017) (2)
- Nivolumab with or without Relatlimab in Untreated Advanced Melanoma. Reply. (2022) (2)
- Analysis of pyrexia in patients (pts) treated with dabrafenib (D) and/or trametinib (T) across clinical trials (2019) (2)
- A phase II study of neoadjuvant pembrolizumab and lenvatinib for resectable stage III melanoma: The neopele study. (2020) (2)
- Perspectives in melanoma: meeting report from the “Melanoma Bridge” (December 5th–7th, 2019, Naples, Italy) (2020) (2)
- Germline variants are associated with increased primary melanoma tumor thickness at diagnosis (2020) (2)
- Circulating tumor DNA (ctDNA) in metastatic melanoma (MM) patients (pts) with brain metastases (mets). (2019) (2)
- Successful treatment of eruptive keratoacanthomas with actitretin for patients on checkpoint inhibitor immunotherapy (2022) (2)
- 1049P Clinical models to predict response in mucosal melanoma (MM) patients (pts) treated with anti-PD-1 (PD1) or combined with ipilimumab (PD1+IPI) (2021) (2)
- Adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma: Health-related quality of life from the randomized phase 3 KEYNOTE-716 study. (2022) (2)
- BRAF (v600e) and NRAS (q61r/q61l) mutation analysis using immunohistochemistry: Implications for routine mutation testing of melanoma samples. (2016) (2)
- Australian general practitioners' attitudes and knowledge of sentinel lymph node biopsy in melanoma management. (2020) (2)
- Epigenetic pro fi ling for the molecular classi fi cation of metastatic brain tumors (2019) (2)
- Analysis of patients (pts) with in-transit metastases treated with nivolumab (NIVO) or ipilimumab (IPI) in CheckMate 238. (2021) (2)
- Higher polygenic risk for melanoma is associated with improved survival in a high ultraviolet radiation setting (2022) (2)
- 1100P Restricted mean survival time (RMST) and cure-rate modeling in estimating survival benefit with adjuvant dabrafenib (D) plus trametinib (T) treatment in melanoma (2020) (2)
- Patterns of acquired resistance to anti-PD-1 antibodies in patients with metastatic melanoma (MM) (2015) (2)
- Neoadjuvant Immunotherapy in Melanoma – The New Frontier (2021) (2)
- Durability of response to immune checkpoint inhibitors (ICI) in metastatic Merkel cell carcinoma (mMCC) after treatment cessation. (2021) (2)
- BRAF mutation testing for patients diagnosed with stage III or stage IV melanoma: practical guidance for the Australian setting (2021) (2)
- Development of melanoma clinical quality indicators for the Australian melanoma clinical outcomes registry (MelCOR): A modified Delphi study (2022) (2)
- Estimate of long-term relapse-free survival (RFS) and analysis of baseline factors associated with RFS in the COMBI-AD trial. (2018) (2)
- Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with BRAF V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i) (2022) (2)
- Adjuvant immunotherapy recommendations for stage III melanoma: physician and nurse interviews (2021) (2)
- Acute bilateral phrenic nerve neuropathy causing hypercapnic respiratory associated with checkpoint inhibitor immunotherapy (2021) (2)
- Rechallenge with combination ipilimumab and anti-PD-1 (IPI+PD1) in metastatic melanoma after acquired resistance to IPI+PD1 immunotherapy (2019) (2)
- PD-L1 and CD8 expression and association with outcomes in patients (pts) with BRAF V600E/K–mutant metastatic melanoma (MM) who received dabrafenib + trametinib (D+T) in the randomized phase 3 COMBI-v study. (2017) (2)
- An app to increase cross-referral and recruitment to melanoma clinical trials. (2016) (2)
- Dabrafenib (D) and trametinib (T) plus spartalizumab (S) in patients (pts) with previously untreated BRAF V600–mutant unresectable or metastatic melanoma: Three-year overall survival (OS) data from the randomized part 3 of the phase III COMBI-i trial. (2022) (2)
- The nature and management of acquired resistance to PD1-based therapy in melanoma. (2020) (2)
- Mo1877 Infliximab for the Treatment of Ipilimumab (anti CTLA-4) and Nivolumab/Pembrolizumab (anti-PD-1) Associated Colitis (2016) (2)
- Effectiveness and Safety of Traditional Chinese Medicine Injection Combined with CF Chemotherapy Regimen in the Treatment of Breast Cancer:Network Meta-analysis and Trial Sequential Analysis (2016) (2)
- Anchored Multiplex PCR Custom Melanoma Next Generation Sequencing Panel for Analysis of Circulating Tumor DNA (2022) (2)
- Association between baseline disease characteristics and relapse-free survival (RFS) in patients (pts) with BRAF V600-mutant resected stage III melanoma treated with adjuvant dabrafenib (D) + trametinib (T) or placebo (PBO). (2019) (2)
- Efficacy of immune checkpoint inhibitors (ICIs) for in-transit melanoma. (2019) (2)
- Is chemotherapy still an option in the treatment of melanoma? (2015) (2)
- Reinvigorating tumour-infiltrating lymphocytes from checkpoint inhibitor resistant melanomas (2018) (2)
- Activity and safety of third-line BRAF-targeted therapy (TT) following first-line TT and second-line immunotherapy (IT) in advanced melanoma. (2020) (2)
- Targeted therapy for the adjuvant treatment of stage III BRAF-mutated melanoma. (2018) (1)
- Sentinel node biopsy for melanoma: The medical oncology perspective. (2015) (1)
- Abstract CT120: A randomized, open-label, open-platform, Phase II study evaluating the efficacy and safety of novel spartalizumab (PDR001) combinations in previously treated unresectable or metastatic melanoma (PLATforM) (2019) (1)
- Characterization of the treatment-naive immune microenvironment in melanoma with BRAF mutation (2022) (1)
- Multiple eruptive squamoproliferative lesions during anti‐PD1 immunotherapy for metastatic melanoma: Pathogenesis, immunohistochemical analysis and treatment (2022) (1)
- Abstract 2761: CODEX highly multiplex image mapping to CITEseq datasets reveal the spatial dynamics of the TME during the development of acquired resistant in immunotherapy treated melanoma (2021) (1)
- NEMO: A Phase 3 Trial of Binimetinib (MEK162) Versus Dacarbazine in Patients With Advanced NRAS-Mutant Melanoma Who Are Untreated or Have Progressed After Immunotherapy (2014) (1)
- Bilateral facial neuritis associated with dabrafenib and trametinib after failure of neoadjuvant immunotherapy for stage III melanoma (2021) (1)
- Circulating tumor DNA (ctDNA) kinetics to predict survival in patients (pts) with unresectable or metastatic melanoma treated with dabrafenib (D) or D + trametinib (T). (2019) (1)
- Reply to ‘Comment on ‘Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy'' (2017) (1)
- Real-world outcomes with ipilimumab and nivolumab in advanced melanoma: a multicentre retrospective study. (2022) (1)
- Clinical factors and overall survival (OS) associated with patterns of metastases (mets) in melanoma patients (pts) (2019) (1)
- Tumor CD155 Drives Resistance to Immunotherapy by Downregulating the Activating Receptor CD226 in CD8 + T Cells (2019) (1)
- 1091PDCOMBI-D: QUALITY OF LIFE (QOL) IMPACT OF THE COMBINATION OF DABRAFENIB AND TRAMETINIB (D + T) VERSUS DABRAFENIB MONOTHERAPY (D) IN PATIENTS WITH BRAF V600E/K UNRESECTABLE OR METASTATIC MELANOMA IN A PHASE III TRIAL. (2014) (1)
- Tumor microenvironment (TME), longitudinal biomarker changes, and clinical outcome in patients (pts) with advanced BRAF V600–mutant melanoma treated with first-line spartalizumab (S) + dabrafenib (D) + trametinib (T). (2019) (1)
- Abstract CT188: 5-year survival and other long-term outcomes from KEYNOTE-006 study of pembrolizumab (pembro) for ipilimumab (ipi)-naive advanced melanoma (Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA.) (2019) (1)
- P01.15 Personalized combination of neoadjuvant domatinostat, nivolumab (NIVO) and ipilimumab (IPI) in macroscopic stage III melanoma patients stratified according to interferon-gamma (IFN-gamma) signature – the DONIMI study (2020) (1)
- Discrepancies in response and immune-related adverse events (irAE) of anti-PD-1 monotherapy between races and primary sites in patients (pts) with advanced nonacral cutaneous melanoma (NACM). (2021) (1)
- Proteomic phenotyping of metastatic melanoma reveals putative signatures of MEK inhibitor response and prognosis (2018) (1)
- Clinicopathologic Features of V600E and V600K Melanoma—Response (2012) (1)
- Evaluation of two high-throughput proteomic technologies for plasma biomarker discovery in immunotherapy-treated melanoma patients (2017) (1)
- Author Correction: Pan-cancer analysis of whole genomes (2023) (1)
- Phase 3 Randomized Eortc 1325-Mg/Keynote-054 Study Results: Pembrolizumab Versus Placebo after Complete Resection in Patients with High-Risk Stage III Melanoma (2018) (1)
- The impact of obesity on outcomes in metastatic melanoma (MM) patients (pts) treated with dabrafenib and trametinib. (2016) (1)
- Mutational and immune gene expression profiling at relapse in patients (pts) treated with adjuvant dabrafenib plus trametinib (D + T) or placebo (pbo) in the COMBI-AD trial. (2018) (1)
- Continental differences in pathologic response with neoadjuvant ipilimumab (IPI) plus nivolumab (NIVO) in patients with macroscopic stage III melanoma in the phase II OpACIN-neo trial (2019) (1)
- Oncology patients' attitudes toward, and experiences with, somatic mutation tumour testing (2015) (1)
- Targeting wild-type TP53 using AMG 232 in combination with MAPK inhibition in Metastatic Melanoma; a phase 1 study (2022) (1)
- Combined ipilimumab and nivolumab first-line and after BRAF-directed targeted therapies in advanced melanoma patients. (2018) (1)
- Health-related quality-of-life (HRQOL) impact of dabrafenib (D) and trametinib (T) vs BRAF inhibitor (BRAFi) monotherapy by lactate dehydrogenase (LDH) in patients (pts) with BRAF V600–mutant melanoma (2016) (1)
- Reflectance confocal microscopy – a non‐invasive tool for monitoring systemic treatment response in stage III unresectable primary scalp melanoma (2022) (1)
- Health-related quality of life (HRQoL) with pembrolizumab (pembro) in resected high-risk stage II melanoma in the phase 3 KEYNOTE-716 study. (2022) (1)
- Phase III KEYNOTE-716 study: Adjuvant therapy with pembrolizumab versus placebo in resected high-risk stage II melanoma. (2019) (1)
- Abstract 3271: Different pathologic response rates between Australia and Europe in macroscopic stage III melanoma patients upon neoadjuvant ipilimumab plus nivolumab in the phase II OpACIN-neo trial (2020) (1)
- Health-related quality of life in stage III melanoma patients treated with neoadjuvant ipilimumab and nivolumab followed by index lymph node excision only, compared to therapeutic lymph node dissection: First results of the PRADO trial. (2020) (1)
- Circulating tumor DNA (ctDNA) in patients (pts) with metastatic uveal melanoma (UM) treated with protein kinase C inhibitor (PKCi). (2020) (1)
- Elevated non-coding promoter mutations are associated with malignant transformation of melanocytic naevi to melanoma. (2022) (1)
- Correlation between pre-existing MEK1P124 mutations and clinical and in vitro response to BRAF inhibitors in metastatic melanoma. (2014) (1)
- Adjuvant therapy with nivolumab versus placebo in patients with resected stage IIB/C melanoma (CheckMate 76K) (2023) (1)
- Pathologist initiated reflex BRAF mutation testing in metastatic melanoma: experience at a specialist melanoma treatment centre. (2022) (1)
- Musculoskeletal immune‐related adverse events with the use of checkpoint inhibitors in malignancy (2020) (1)
- Phase Ib/II, open-label, dose-escalation study of LGX818, an oral selective BRAF inhibitor, in combination with MEK162, an oral MEK1/2 inhibitor, in patients with BRAF V600-dependent advanced solid tumors: preliminary results (2014) (1)
- Hotspot KRAS mutations in brain metastases at the first metastatic recurrence of cutaneous melanoma (2020) (1)
- Tu1243 - Checkpoint Inhibitor Immunotherapy Side-Effects in GI Practice (2018) (1)
- Primary analysis of a phase 2, open-label, multicenter trial of talimogene laherparepvec (T-VEC) plus pembrolizumab (pembro) for the treatment (Tx) of patients (pts) with advanced melanoma (MEL) who progressed on prior anti–PD-1 therapy: MASTERKEY-115. (2022) (1)
- Corrigendum to "Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study*" [Eur J Cancer 91 (2018) 116-124]. (2018) (1)
- Melanoma brain metastases: the outcome of whole brain radiation therapy in the era of effective systemic therapy (2021) (1)
- 113 A case of suspected autoimmune encephalitis secondary to nivolumab (2019) (1)
- Nivolumab improved survival vs dacarbazine in patients with untreated advanced melanoma (2015) (1)
- Obesity is associated with altered tumor metabolism in metastatic melanoma. (2022) (1)
- Dataset of a retrospective multicenter cohort study on characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis (2022) (1)
- Clinicopathologic characteristics of immune colitis in melanoma patients treated with combination ipilimumab and anti-PD1 (IPI+PD1) and PD1 monotherapy (2019) (1)
- Treatment outcomes in patients (pts) with melanoma brain metastases (MBM) treated with systemic therapy: A systematic literature review (SLR) and meta-analysis. (2021) (1)
- Characteristics of Patients With a Complete Response Treated With Dabrafenib + Trametinib Combination Therapy: Findings From Pooled COMBI-d and COMBI-v 5-Year Analysis (2020) (1)
- Management of resected stage III/IV melanoma with adjuvant immunotherapy. (2021) (1)
- Reply to E. Hindié and K.R. Hess. (2019) (1)
- Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma - Authors' reply. (2021) (1)
- Antitumor activity of ipilimumab after pembrolizumab in patients with advanced melanoma in KEYNOTE-006 (2017) (1)
- BRAF/MEK inhibition in melanoma patients with rare BRAF mutations. (2018) (1)
- Cutaneous clear cell sarcoma with an epidermal component mimicking melanoma. (2021) (1)
- Circulating tumor DNA (ctDNA) using Guardant360 to predict response in BRAF V600 WT metastatic melanoma (MM) patients (pts) receiving immune checkpoint inhibitors (ICI). (2020) (1)
- Abstract 913: Defining melanoma patients unresponsive to single agent anti-PD-1 therapy but responsive to combination anti-PD-1 + anti-CTLA-4 therapy (2020) (1)
- Tumor-associated B-cells induce tumor heterogeneity and therapy resistance (2017) (1)
- Abstract B16: NEMO: A phase 3 trial of binimetinib (MEK162) versus dacarbazine in patients with advanced NRAS-mutant melanoma who are untreated or have progressed on or after immunotherapy (2015) (1)
- Effect on Health-Related Quality of Life of Adjuvant Treatment with Dabrafenib plus Trametinib in Patients with Resected Stage III BRAF-Mutant Melanoma (2018) (1)
- Estimation of Distant Metastasis-free Survival in Trials of Adjuvant Therapy for Melanoma. Reply. (2019) (1)
- Clinical models to predict response and survival in metastatic melanoma (MM) patients (pts) treated with anti-PD-1 alone (PD1) or combined with ipilimumab (IPI+PD1). (2019) (1)
- Lack of association between anatomical sites of scalp melanomas and brain metastases does not support direct vascular spread (2022) (0)
- Patterns and management of progression on first-line ipilimumab combined with anti-PD-1 (IPI+PD1) in metastatic melanoma (MM) patients. (2021) (0)
- Cutaneous toxicities of MAPK inhibitors: BRAF inhibitors, MEK inhibitors and combination therapy. A case series from an Australian institution (2013) (0)
- Health-related quality of life in patients with melanoma brain metastases treated with immunotherapy. (2023) (0)
- Comparative Genomics Provides Etiologic and Biological Insight into Melanoma Subtypes (2022) (0)
- Successful Manufacturing of Tumor-Infiltrating Lymphocyte (TIL) Cell Therapy from Cryopreserved Melanoma Tumors Shipped from Australia (2022) (0)
- Efficacy of pembrolizumab (Pembro) in patients (Pts) with advanced melanoma with stable brain metastases (BM) at baseline: A pooled retrospective analysis. (2018) (0)
- 中国語発表乳癌の無作為対照試験における不良反応報告品質評価【JST・京大機械翻訳】 (2016) (0)
- Neoadjuvant Checkpoint Immunotherapy and Melanoma: The Time Is Now. (2023) (0)
- Reply to E. Hindié. (2021) (0)
- Transcriptomic and immunophenotypic profiles of melanoma tissue from patients (pts) treated with anti-PD-1 +/- ipilimumab to define mechanisms of response and resistance. (2018) (0)
- First results on distant metastasis-free survival in stage II melanoma (2022) (0)
- Abstract CT001: Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: Efficacy and safety results from the EORTC 1325-MG/Keynote 054 double-blinded phase III trial (2018) (0)
- 194 A multicenter characterization of chronic toxicities following adjuvant anti-PD-1 therapy for high risk resected melanoma (2020) (0)
- Whole exome paraffin sequencing (WEPS) of same-patient (pt) primary, extracranial, and melanoma brain metastases (PEB) to identify new driver and clonal evolution genetic events. (2015) (0)
- Efficacy of adjuvant radiotherapy in recurrent melanoma after adjuvant immunotherapy. (2021) (0)
- Abstract 2009: Evaluation of RNA-sequencing signatures with response to pembrolizumab (pembro) monotherapy in ipilimumab-naive patients (pts) with melanoma (2020) (0)
- The “Great Debate” at Melanoma Bridge 2021, December 2nd–4th, 2021 (2022) (0)
- 35. Factors predictive of clinical outcomes in patients with thin cutaneous melanoma (2011) (0)
- 426 MK-3475-U02: Phase 1/2 study of investigational agents with or without pembrolizumab versus pembrolizumab monotherapy in melanoma (2020) (0)
- Abstract A04: Analysis of molecular and immune features that correlate with serum lactate dehydrogenase (LDH) levels in patients (pts) with metastatic melanoma (2020) (0)
- Reply to A. Shinde et al. (2019) (0)
- Distinct Immune Cell Popu lations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1 / Anti-CTLA-4 Combined Therapy Graphical (2019) (0)
- 中国の非小細胞肺癌の無作為対照試験方法論と倫理学報告品質評価【JST・京大機械翻訳】 (2016) (0)
- Clinical validation study of circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib (2021) (0)
- Blood, biomarkers and beyond. Abstracts of the Medical Oncology Group of Australia Incorporated Annual Scientific Meeting. July 31-August 2, 2013. Melbourne, Victoria, Australia. (2013) (0)
- Mucosal-associated invariant T (MAIT) cells are activated in the gastrointestinal tissue of patients with combination ipilimumab and nivolumab therapy-related colitis in a pathology distinct from ulcerative colitis. (2020) (0)
- Understanding the Tumour Immune Microenvironment (TIME) at different sites of MELANOMA Metastases (METS) (2020) (0)
- Tissue-based activation of mucosal-associated invariant T (MAIT) cells in combination ipilimumab and nivolumab checkpoint inhibitor (CI) colitis (2019) (0)
- Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436). (2011) (0)
- Circulating tumor DNA as a biomarker in metastatic melanoma patients treated with anti-PD1 antibodies (2016) (0)
- Abstract 2650: In depth immune profiling of the response of melanoma to MAPK inhibition (2016) (0)
- Assessment the methodological and ethical quality of randomized controlled trials of non-small cell lung cancer in China (2016) (0)
- 中国語が乳癌の無作為対照試験報告の品質評価を発表した。【JST・京大機械翻訳】 (2016) (0)
- Abstract CT032: Trials in progress: a global phase 1/1b clinical trial evaluating exarafenib (KIN-2787), a highly selective pan-RAF inhibitor, in adult patients with BRAF-altered solid tumors and NRAS mutant melanoma (2023) (0)
- Distant metastasis-free survival with adjuvant pembrolizumab for resected stage IIB or IIC melanoma - Authors' reply. (2023) (0)
- Efficacy and safety of immune checkpoint inhibitors in young adults with metastatic melanoma. (2022) (0)
- (S029) Development of an Immune-Associated Molecular Signature Predicting Melanoma Survival (2017) (0)
- Pre-treatment circulating cytokines predict toxicity with combination anti-PD1 and anti-CTLA4 immunotherapy. (2018) (0)
- Abstract 3246: Dynamics of T-cell checkpoint receptor profiles during melanoma progression (2019) (0)
- Biomarkers of response and resistance to combined anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients utilising multiplex immunofluorescence (2018) (0)
- Correction to: Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC) (2022) (0)
- The “Great Debate” at Melanoma Bridge 2021, December 2nd–4th, 2021 (2022) (0)
- Clinical features and response to immune checkpoint inhibitors (ICIs) in pregnancy-associated melanoma (PAM). (2019) (0)
- Abstract CT002: KEYMAKER-U02 substudy 02C: neoadjuvant pembrolizumab (pembro) + vibostolimab (vibo) or gebasaxturev (geba) or pembro alone followed by adjuvant pembro for stage IIIB-D melanoma (2023) (0)
- Clinical characteristics and survival of BRAF-mutant metastatic melanoma patients (pts) treated with the BRAF inhibitors (BRAFi) dabrafenib or vemurafenib beyond disease progression (PD) (2013) (0)
- Publisher Correction: Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma (2019) (0)
- Response to Letter to the Editor: “Checkpoint Inhibitor-Associated Autoimmune Diabetes is Distinct From Type 1 Diabetes” (2020) (0)
- Analysis of clinical and molecular profiles of patients with innate resistance to ANTI-PD-1 +/- ANTI-CTLA-4 immunotherapy in metastatic melanoma (2021) (0)
- Restricted Mean Survival Time and Cure-Rate Modeling in Estimating Relapse-Free Survival Benefit With Adjuvant Dabrafenib + Trametinib Treatment in Melanoma (2021) (0)
- Overall Survival and Response with Nivolumab and Relatlimab in Advanced Melanoma (2023) (0)
- Adjuvant Therapy in Resected Melanoma. (2018) (0)
- 1075P Regression tree analysis to identify factors associated with relapse-free survival (RFS) in patients with resected stage III BRAF V600E/K–mutant melanoma (2021) (0)
- 1257TiPKEYNOTE 029: Phase 1/2 randomized study of pembrolizumab (pembro) plus 2 dose regimens of ipilimumab (ipi) for advanced melanoma (2017) (0)
- Analysis of patient-reported outcomes by disease progression status in patients (pts) with BRAF V600–mutant metastatic melanoma in the COMBI-d and COMBI-v trials (2016) (0)
- PD-L1 expression, immune cell correlates, and PD-1+ lymphocytes in sentinel lymph node positive melanoma patients: Implications for adjuvant PD-1 clinical trials. (2015) (0)
- 【目的】ウサギの皮膚ケラチン遺伝子の転写に及ぼす亜ヒ酸ナトリウムの影響を研究する。【JST・京大機械翻訳】 (2016) (0)
- Neoadjuvant dabrafenib and trametinib (D+T) for stage III melanoma: Long-term results from the NeoCombi trial. (2022) (0)
- Factors influencing acceptance, adoption and adherence to sentinel node biopsy recommendations in the Australian Melanoma Management Guidelines: a qualitative study using an implementation science framework (2022) (0)
- BRAF Inhibitor Treatment BRAF-Mutant Melanoma Patients during Growth Factor Serum Levels in Dynamics of Chemokine , Cytokine , and (2014) (0)
- Case series: Immune checkpoint inhibitor-induced transverse myelitis (2023) (0)
- 21. Recurrent hotspot SF3B1 mutations in mucosal melanoma: Frequency and impact on survival (2019) (0)
- bcGST - an interactive bias-correction method to identify over-represented gene-sets in boutique arrays (2017) (0)
- Abstract A154: Flow cytometric analysis of immune responses in the melanoma tissue biopsies before or during anti-PD1 immunotherapy (2019) (0)
- Re-defining the role of surgery in the management of patients with oligometastatic stage IV melanoma in the era of effective systemic therapies. (2021) (0)
- PO-513 Using MAPK and PI3K signalling to predict patient outcome in resectable stage IIIB/C melanoma patients neoadjuvantly treated with dafrafenib and trameitinib (2018) (0)
- Translating Basic Cancer Discoveries to the Clinic. (2020) (0)
- Analysis of mutational burden and adaptive immune response in desmoplastic melanomas treated with PD-1/L1 inhibitors. (2017) (0)
- Mutational analysis of undifferentiated melanoma (2020) (0)
- Outcome and Prognostic Factors of Stereotactic Radiosurgery (SRS) for Melanoma Brain Metastases (MBM) in Era of Effective Systemic Therapy. (2016) (0)
- The critical role of tumour-resident cytotoxic T cells in human malignancies (2018) (0)
- Phase II Three-Arm Randomised Study of the Braf Inhibitor (BRAFI) Dabrafenib Alone vs Combination with Mek1/2 Inhibitor (MEKI) Trametinib in Pts with Braf V600 Mutation-Positive Metastatic Melanoma (MM) (2012) (0)
- PO-414 Stage IV melanoma patients with tumoural MHC class i loss only respond to anti-PD-1 therapy in the presence of high NK cell density (2018) (0)
- Effect of the SunSafe Student Ambassador Program on the attitudes, knowledge and behaviour of Australian high‐school students towards sun safety: a prospective study (2022) (0)
- 24. Analysis of indoleamine 2,3-dioxygenase expression in longitudinal primary, nodal and distant metastatic melanoma specimens (2019) (0)
- Characterisation of peripheral blood mononuclear cells in patients with combination ipilimumab and nivolumab therapy-related colitis (2019) (0)
- 漢方薬注射剤とCF化学療法の併用による乳癌の有効性と安全性の治療のためのネットワークのMETA分析と試験の逐次分析【JST・京大機械翻訳】 (2016) (0)
- Safety and Activity of Combined Radiation Therapy (RT) and Anti-PD-1 Antibodies (PD-1) in Patients (pts) With Metastatic Melanoma (2015) (0)
- Intratumoral CD16+ macrophages are associated with clinical outcomes of patients with metastatic melanoma treated with combination anti-PD-1 and anti-CTLA-4 therapy. (2023) (0)
- Advanced melanoma patients with high CD16+ macrophages have better response and survival to anti-PD-1 based immunotherapy (2019) (0)
- Abstract 6747: Sites of metastases prior to systemic treatment influence progression patterns and survival in stage IV melanoma patients (2023) (0)
- P1.04-11 Exploring the Germ-Line Contribution to Exceptional Response to PD-1/PD-L1 Inhibition in Patients with NSCLC by Whole Genome Sequencing (2018) (0)
- 1084P PLATForM: Descriptive analysis from a randomised, phase II study of novel spartalizumab combinations in previously treated unresectable/metastatic melanoma (2021) (0)
- Author Correction: Tumour gene expression signature in primary melanoma predicts long-term outcomes (2022) (0)
- ASO Visual Abstract: Survival Outcomes of Salvage Metastasectomy after Failure of Modern-Era Systemic Therapy for Melanoma (2021) (0)
- Novel Immune Targets in Melanoma—Response (2019) (0)
- Abstract 5025: Immune expression profiling of MAPK inhibitor resistant tumors based upon mechanisms of resistance (2015) (0)
- 中国語で発表された非小細胞肺癌の無作為対照試験要約報告書の品質評価【JST・京大機械翻訳】 (2016) (0)
- Abstract CT065: KEYNOTE 029: A phase I/II randomized trial of pembrolizumab (pembro) plus 2 dose regimens of ipilimumab (ipi) for advanced melanoma (2017) (0)
- Efficacy of ipilimumab 3 mg/kg following progression on low-dose ipilimumab in metastatic melanoma. (2022) (0)
- Association Between Baseline Disease Characteristics and Relapse-Free Survival in Patients With BRAF V600–Mutant Resected Stage III Melanoma Treated With Adjuvant Dabrafenib + Trametinib or Placebo (2019) (0)
- Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma (2019) (0)
- Comparable responses of melanoma at primary site and synchronous lymph node metastases upon neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) (2019) (0)
- Chapter 5 – Brain Metastases from Melanoma (2016) (0)
- 38. INTRALESIONAL MOLECULAR HETEROGENEITY IN A BRAF-MUTANT BRAF INHIBITOR RESISTANT MELANOMA: A CASE ILLUSTRATING THE CHALLENGES FOR PERSONALISED MEDICINE (2013) (0)
- Phenotypic Differences in Thyroid Immune Related Adverse Events Following Treatment With Immune Checkpoint Inhibitors (2021) (0)
- Durability of response to immune checkpoint inhibitors in metastatic Merkel cell carcinoma after treatment cessation. (2023) (0)
- Pooled analysis of factors to predict durable clinical outcomes with combination dabrafenib (D) and trametinib (T) across registration trials (2016) (0)
- Assessment of the prognostic role of regression in primary cutaneous melanoma (2020) (0)
- Efficacy and toxicity of adjuvant radiotherapy in recurrent melanoma after adjuvant immunotherapy (2023) (0)
- Adjuvant dabrafenib plus trametinib (D + T) versus placebo in patients with resected stage III BRAFV600-mutant melanoma: Updated 5-year distant metastases-free survival (DMFS) analysis of COMBI-AD. (2022) (0)
- Abstract CT250: A first-in-human phase 1 study of NL-201 in patients with relapsed or refractory cancer (2022) (0)
- Erratum (2014) (0)
- 1499P Health-related quality of life in stage III melanoma patients treated with neoadjuvant ipilimumab and nivolumab: Week 60 update of the PRADO trial (2021) (0)
- Clinical features associated with outcomes and biomarker analysis of dabrafenib plus trametinib treatment in patients with BRAF-mutant melanoma brain metastases. (2022) (0)
- Spartalizumab in Combination With Dabrafenib And Trametinib in Advanced BRAF V600–Mutant Melanoma: Efficacy, Safety, and Biomarker Findings in Parts 1 and 2 of COMBI-i (2020) (0)
- Systemic LRG1 Expression in Melanoma is Associated with Disease Progression and Recurrence (2023) (0)
- 3304 Metabolic activity in metastatic melanoma after long-term treatment with anti-PD-1 antibodies (2015) (0)
- Perspectives in melanoma: meeting report from the “Melanoma Bridge” (December 5th–7th, 2019, Naples, Italy) (2020) (0)
- The role of CD16+ NK cells and CD16+ CD56– cells in predicting response to anti-PD-1 therapy (2018) (0)
- Inhibition of Oncogenic BRAF Triggers Immunogenic Necrosis of Human Melanoma Cells (2013) (0)
- Prognostic and predictive value of metformin in the EORTC 1325/KEYNOTE- 054 phase III trial of pembrolizumab vs placebo in resected high-risk stage III melanoma (2023) (0)
- Phase 1b study of cobimetinib plus atezolizumab in patients with advanced BRAFV600 wild-type melanoma progressing on prior anti-programmed death-1 therapy. (2022) (0)
- A phase II, open-label, randomized, multicenter trial of encorafenib + binimetinib evaluating a standard-dose and a high-dose regimen in patients with BRAFV600-mutant melanoma brain metastasis (MBM) (POLARIS) (2019) (0)
- Association of baseline corticosteroid treatment with outcomes for patients (pts) with BRAF-mutant melanoma brain metastases (MBMs) in COMBI-MB treated with dabrafenib and trametinib (DT). (2022) (0)
- Management of infliximab-refractory immune checkpoint inhibitor gastrointestinal toxicity: A multicenter case series. (2022) (0)
- A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis (2019) (0)
- Comprehensive Clinical, Histopathologic, and Molecular Analysis and Long-term Follow-up of Patients With Nodal Blue Nevi (2022) (0)
- Neurological adverse effects associated with anti-PD1 antibodies alone or in combination with ipilimumab: a multicenter case series (2022) (0)
- OTHR-08. PREDICTION OF RISK OF CENTRAL NERVOUS SYSTEM METASTASIS FOR AJCC 8TH EDITION STAGE III MELANOMA PATIENTS (2019) (0)
- Abstract LB-121: Exploring the germ-line contribution to exceptional response to PD-1/PD-L1 inhibition in patients with metastatic non-small-cell lung cancer by whole genome sequencing (2018) (0)
- CLINICAL FEATURES AND OUTCOMES OF CARDIAC INVOLVEMENT IN PATIENTS WITH CANCER TREATED WITH IMMUNE CHECKPOINT INHIBITORS (2023) (0)
- 早期乳腺癌における全乳腺大分割放射線療法と通常の放射線治療効果と安全性の系統的評価【JST・京大機械翻訳】 (2016) (0)
- Genomic Landscape of Patient-matched Tumor and Circulating Cell-free DNA in Metastatic Melanoma (2019) (0)
- Abstract 2762: Spatial distribution and immune cell infiltration at different sites of melanoma metastases (mets) (2021) (0)
- Clinicopathological characteristics of new primary melanomas in patients receiving immune checkpoint inhibitor therapy for metastatic melanoma (2022) (0)
- Health-related quality of life with nivolumab plus relatlimab versus nivolumab monotherapy in patients with previously untreated unresectable or metastatic melanoma: RELATIVITY-047 trial, (2023) (0)
- Making a difference to many (2019) (0)
- 3345 COMBI-v: health-related quality of life (HRQoL) impact of the combination of dabrafenib and trametinib (D+T) vs vemurafenib (V) in patients with BRAF V600 metastatic melanoma (MM) (2015) (0)
- Genomic alterations in metastatic basal cell carcinoma (2020) (0)
- IMMU-04. TEMPORAL AND SPATIAL MODULATION OF THE IMMUNE RESPONSE OF THE MURINE GL261 GLIOMA TUMOUR MICROENVIRONMENT (2019) (0)
- Pharmacokinetic and pharmacodynamic analysis of preoperative therapy with dabrafenib alone and in combination with trametinib in patients with BRAF mutation–positive melanoma with metastases to the brain (BRV116521). (2014) (0)
- 1139P Long-term safety profile of pembrolizumab monotherapy and relationship with clinical outcome: A pooled analysis of patients with advanced melanoma (2020) (0)
- Higher response rates for concurrent triple therapy versus sequential therapy in melanoma (2022) (0)
- 1054P FDG-PET to predict long-term outcome from anti-PD1 (PD1) therapy in metastatic melanoma (2021) (0)
- Abstract A024: Protein microarrays for the immunological profiling of melanoma (2016) (0)
- 1259TiPA randomized, double-blind, placebo-controlled, phase III study comparing the combination of PDR001, dabrafenib and trametinib versus placebo, dabrafenib and trametinib in previously untreated patients with unresectable or metastatic BRAF V600–mutant melanoma (COMBI-i) (2017) (0)
- Melanoma Therapy Overview at SMR 2013 (2013) (0)
- Differences in immune profiles of metastatic melanoma patients treated with anti-CTLA-4 and anti-PD-1 combined immunotherapy. (2017) (0)
- Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma (2019) (0)
- Melanoma and immunotherapy bridge 2015 (2016) (0)
- 1106P International experience of ipilimumab and nivolumab in patients with advanced melanoma (2020) (0)
- Making a difference to many (2019) (0)
- Temporal and spatial modulation of the immune response of the murine Gl261 glioma tumor microenvironment (2019) (0)
- Abstract 2221: Molecular analysis finds excision margin width predictive of recurrence in acral melanoma (2022) (0)
- 中国語発表乳癌の無作為対照試験の倫理的品質評価【JST・京大機械翻訳】 (2016) (0)
- Rare immune-related adverse events in patients with melanoma: incidence, spectrum, and clinical presentations (2023) (0)
- Learning from clinical trials of neoadjuvant checkpoint blockade (2020) (0)
- Genomic Profiling of Metastatic Basal cell Carcinoma Reveals Candidate Drivers of Disease and Therapeutic Targets. (2023) (0)
- Causes, consequences and clinical significance of aneuploidy across melanoma subtypes (2022) (0)
- 23. Prevalence and expression profile of immune checkpoint receptors in untreated human melanoma (2019) (0)
- Cross-platform comparison of immune signatures in immunotherapy-treated patients with advanced melanoma using a rank-based scoring approach (2023) (0)
- A case series of immune checkpoint inhibitor induced diabetes mellitus (ICI-DM). (2018) (0)
- The molecular and functional landscape of resistance to immune checkpoint blockade in melanoma (2023) (0)
- Reinvigorating tumour-infiltrating lymphocytes from checkpoint inhibitor resistant melanomas (2018) (0)
- IFNγ signaling sensitizes melanoma cells to BH3 Mimetics. (2023) (0)
- General practitioners’ involvement in diagnosing, treating and referring patients with suspected or confirmed primary cutaneous melanoma: a qualitative study (2019) (0)
- General practitioners’ involvement in diagnosing, treating and referring patients with suspected or confirmed primary cutaneous melanoma: a qualitative study (2019) (0)
- Durable Responses to Anti-PD1 and Anti-CTLA4 in a Preclinical Model of Melanoma Displaying Key Immunotherapy Response Biomarkers (2022) (0)
- The effect of organ-specific tumor microenvironments on response patterns to immunotherapy (2022) (0)
- Abstract 5701: Predictive biomarker models of immunotherapy response in patients with metastatic melanoma: genomic, transcriptomic, and immune profiles from the Personalised Immunotherapy Program (PIP) (2023) (0)
- Higher polygenic risk for melanoma is associated with improved survival in a high ultraviolet radiation setting (2022) (0)
- Author Correction: Inferring structural variant cancer cell fraction (2022) (0)
- Epigenetic profiling for the molecular classification of metastatic brain tumors (2018) (0)
- SIRT6 haploinsufficiency induces BRAFV600E melanoma cell resistance to MAPK inhibitors via IGF signalling (2018) (0)
- Molecular Genomic Profiling of Melanocytic Nevi (2019) (0)
- Abstract 81: The association between melanoma liver metastases (mets) and the systemic anti-tumor immune profile (2023) (0)
- Author Correction: Patterns of somatic structural variation in human cancer genomes (2020) (0)
- Whole genome landscapes of uveal melanoma show an ultraviolet radiation signature in iris tumours (2020) (0)
- Author Correction: Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples (2020) (0)
- Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets (2019) (0)
- Clinical significance of intronic variants in BRAF inhibitor resistant melanomas with altered BRAF transcript splicing (2017) (0)
- Utility of next generation sequencing for differentiating malignant PEComa from metastatic melanoma. (2022) (0)
- Author Correction: The evolutionary history of 2,658 cancers (2023) (0)
- Resistance to immunotherapy is associated with high parenchymal PD1+CD8+/CD8+ T cells (PD1tR) driven by tumour CD155 (2019) (0)
- Abstract 2369: Spatial organization of the tumour immune microenvironment (TIME) in primary and metastatic melanoma is associated with patient outcome (2023) (0)
- The mutational landscape of melanoma brain metastases presenting as the first visceral site of recurrence (2020) (0)
- Efficacy and Safety of Hypofractionation Radiotherapy versus Conventional Whole Breast Radiotherapy for Early Stage Breast Cancer after Breast Conserving Surgery: A Systematic Review (2016) (0)
- Abstract IA30: Combined targeted therapies, where to next (2015) (0)
- Benign blue naevi involving lymph nodes: A case series with accompanying molecular data and long term follow-up confirms clinical behaviour (2020) (0)
- Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial. (2023) (0)
This paper list is powered by the following services:
Other Resources About Georgina Long
What Schools Are Affiliated With Georgina Long?
Georgina Long is affiliated with the following schools:
